###begin article-title 0
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
The level of drug metabolism and drug transport is correlated with the sensitivity of cancer cells towards platinum-based chemotherapy. We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Totally 113 patients with advanced NSCLC were routinely treated with platinum-based chemotherapy, and clinical response was evaluated after four cycles. MRP2 C-24T (-24C>T), MRP2 Val417Ile (1249G>A), MRP2 Ile1324Ile (3972C>T), and GSTP1 Ile105Val (342A>G) genotype were determined by gene-chip method (a 3-D (three dimensions) polyacrylamide gel-based DNA microarray method) using DNA samples isolated from peripheral blood collected before treatment. Pearson Chi-square test and Fisher's exact test were performed to measure the differences of the chemotherapeutic efficacy among variant genotype. The odds ratios and 95% confidence intervals were computed by logistic regression.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
The C-->T change of MRP2 C-24T and the A-->G change of GSTP1 Ile105Val polymorphism significantly increased platinum-based chemotherapy response.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 134 142 <span type="species:ncbi:9606">patients</span>
The polymorphic status of MRP2 C-24T and GSTP1 Ile105Val might be the predictive markers for the treatment response of advanced NSCLC patients. The DNA microarray-based method is accurate, high throughput and inexpensive, suitable for single-nucleotide polymorphism genotyping in a large number of individuals.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 995 996 995 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1235 1236 1235 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 92 98 <span type="species:ncbi:9606">people</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 1131 1137 <span type="species:ncbi:9606">person</span>
###xml 1141 1147 <span type="species:ncbi:9606">person</span>
Lung cancer is the most common cause of cancer death in many countries; more than a million people in the world die from the disease each year [1]. About 80% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC), of which nearly two-thirds are detected at advanced stages [2]. Chemotherapy is the major treatment method currently for advanced NSCLC, but the rate of efficacy with standard cytotoxic chemotherapy is only 30-40%, and this level has reached a "therapeutic plateau" [3]. At present, platinum-based double-agent therapies are the major remedial measure of the advanced NSCLC and have been shown to improve the overall survival [4]. Cisplatin is still the scaffolding of combination chemotherapy. Resistance to chemotherapy is also a challenge. Cisplatin resistance can develop as a result of decreased influx or increased efflux of drug, glutathione or metallothionein conjugation, drug detoxification, DNA repair, or skipping lesions during DNA replication [5]. It is more likely that the combination of these mechanisms results in the cisplatin resistance. Because drug resistance varies from person to person, genetic factors are believed to influence the effectiveness of lung cancer treatment [6].
###end p 11
###begin p 12
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
The finding of human genome project indicated that 99% of DNA within different individuals were identical, and only 1% was variant, of which the major one was single-nucleotide polymorphism (SNP). SNP is a point mutation carried by some individuals of a population. The study of pharmacogenetics indicated that such tiny diversity in sequence of genome significantly influenced on individual treatment response, toxicity, and survival in cancer patients. Because the inter-individual variation is necessary for the optimization of medication, the genetic polymorphisms have the potential significance in drug disposition and pharmacokinetics. In addition, SNP has greater clinical significance in terms of its ease of clinical application, rather than its mRNA, which present some clinical difficulties in terms of obtaining tissue samples from lung cancer patients.
###end p 12
###begin p 13
As known, platinum-based drugs inhibit tumor growth mainly by the formation of bulky DNA adducts, and the latter are mainly removed by DNA repair mechanisms, especially by the nucleotide excision repair (NER) mechanisms. Also, our work team has already done some work about the association of DNA repair gene polymorphisms and platinum-based chemotherapy. Moreover, it should not been disregarded that drug metabolism and drug transport also play an important role in response to platinum-based chemotherapy.
###end p 13
###begin p 14
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 873 874 873 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
Phase II metabolising enzymes take advantage of electrophilic groups intrinsically carried in a structure, or introduced by phase I metabolism, to conjugate xenobiotics with donor molecules, such as glutathione (GSH), UDP glucuronic acid, or 3'-phosphoadenosine-5'- phosphosulfate (PAPS). The glutathione S-transferase (GST) family of phase II metabolizing enzymes catalyzes detoxifying endogenous reactions with GSH and protect cellular macromolecules from damage caused by a wide variety of endogenous and exogenous molecules, including cytotoxic, mutagens, carcinogens, and chemotherapeutic agents [7]. The resulting glutathione adducts have increased the solubility and can then be either excreted or further metabolized. In the current lung cancer chemotherapy, many of the commonly used drugs are metabolized by the glutathione system, especially the platinum drugs [8].
###end p 14
###begin p 15
###xml 254 255 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 425 427 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 479 481 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 658 660 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 708 709 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 942 944 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 258 263 <span type="species:ncbi:9606">Human</span>
###xml 400 405 <span type="species:ncbi:9606">human</span>
###xml 1095 1103 <span type="species:ncbi:9606">Patients</span>
The 17 human cytosolic GST subunits are classified as seven gene families according to their biochemical characteristics and amino acid sequence similarities: alpha (GSTA), mu (GSTM), theta (GSTT), pi (GSTP), omega (GSTO), zeta (GSTZ), and sigma (GSTS) [9]. Human GSTs are nearly ubiquitously expressed, and GSTP is the most abundant subunit in lung and brain. GSTP1 is widely expressed in different human epithelial tissue [10] and is the most abundant GST isoform in the lung [11]. GSTP1 conjugates and protects particularly against the cytotoxic effects of some chemotherapeutic agents, including anthracyclines, alkylating agents, and their metabolites [12]. The GST gene families, including glutathione S-transferase P1 (GSTP1), contain several polymorphic loci. At least three of the genes that code for GSTs, GSTM1, GSTT1, and GSTP1, have been found to have functional polymorphisms that are frequently present in general populations [13]. The role of GSTs in the detoxification of antitumor agents suggests the possible implication of GST polymorphisms to the chemotherapeutic response. Patients with a GSTs-null genotype are believed to exhibit impaired detoxification of environmental genotoxic agents and chemotherapeutic drugs, which prompts the hypothesis that allelic variants associated with less effective detoxification of potential antitumor drugs can confer an increased sensitivity to chemotherapy.
###end p 15
###begin p 16
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
In addition to the enzyme, drug transporters are important in determining drug absorption, drug distribution to tissues, and drug excretion in the urine and bile. Some studies have shown that the conjugates formed by GSTs are transported by MRP2 (multidrug resistance protein 2, also designated canalicular multispecific organic anion transporter, cMOAT, or ABCC2 protein), which are the part of the phase III biotransformation system, in an ATP-dependent manner [14, 15]. Furthermore, GSTP1 activity may work synergistically with MRP transport as a tri-GSH conjugate [16].
###end p 16
###begin p 17
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1177 1179 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 243 248 <span type="species:ncbi:9606">human</span>
Multidrug resistance-associated protein 2 are expressed in the outer plasma membrane as well as in intracellular vesicles and the Golgi apparatus. This indicates a role in the sequestration of drugs into vesicles and cellular drug export. The human MRP subfamily contains nine members. MRP2 is a 1,545 amino acid, 190-200 kDa protein having two ATP-binding domains, and 17 transmembrane regions in its sequence [17]. MRP2 belongs to the subfamily C of ABC (ATP-binding cassette) transporter proteins [18], the efflux transporters that have a role in limiting influx and facilitating efflux to prevent the intracellular accumulation of their own substrate compounds [17]. Drugs are detoxified and conjugated in vivo and then exported out of the cells. In tumor cells, such functions confer multidrug resistance for various anticancer agents. MRP2 has broad-substrate specificity and was identified to transport relatively hydrophilic compounds, including the glucuronide, glutathione, and sulfate conjugates of endogenous and exogenous compounds covering organic anions derived from phases I and II metabolism of xenobiotics and anionic anticancer drugs, such as cisplatin [19, 20]. The interindividual variations on activity and expression level of the transporter, due to SNP of MRP2 gene, might be a critical factor in selection of the anticancer drugs.
###end p 17
###begin p 18
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 490 497 <span type="species:ncbi:9606">patient</span>
It has been speculated that SNPs in drug metabolizing enzymes genes and drug transporters genes may alter their expression or activity, affect drug disposition, and in turn influence the effects of cancer treatment [21]. Therefore, we could expect that the lower the levels of expression of GSTP1 and MRP2, the more susceptible the tumors to platinum therapies. Here, a study of 113 NSCLC patients was conducted to evaluate if functional polymorphisms in GSTP1 and MRP2 are associated with patient response to chemotherapy.
###end p 18
###begin title 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 19
###begin title 20
Study subjects
###end title 20
###begin p 21
###xml 1102 1103 1102 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1104 1111 1104 1111 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1111 1178 1111 1178 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22">Patient clinicopathologic characteristics and chemotherapy regimens</p>
###xml 1111 1178 1111 1178 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22">Patient clinicopathologic characteristics and chemotherapy regimens</p></caption>
###xml 1178 1193 1178 1193 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Characteristics</th>
###xml 1193 1204 1193 1204 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient no.</th>
###xml 1204 1207 1204 1207 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">(%)</th>
###xml 1178 1207 1178 1207 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Characteristics</th><th align="left">Patient no.</th><th align="left">(%)</th></tr>
###xml 1178 1207 1178 1207 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Characteristics</th><th align="left">Patient no.</th><th align="left">(%)</th></tr></thead>
###xml 1207 1218 1207 1218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Age (years)</td>
###xml 1207 1218 1207 1218 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Age (years)</td></tr>
###xml 1218 1233 1218 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Median (range)</td>
###xml 1233 1245 1233 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">59.6 (34-84)</td>
###xml 1245 1245 1245 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1218 1245 1218 1245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Median (range)</td><td align="left">59.6 (34-84)</td><td align="left"/></tr>
###xml 1245 1251 1245 1251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Gender</td>
###xml 1245 1251 1245 1251 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Gender</td></tr>
###xml 1251 1258 1251 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Female</td>
###xml 1258 1260 1258 1260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">37</td>
###xml 1260 1264 1260 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">32.7</td>
###xml 1251 1264 1251 1264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Female</td><td align="left">37</td><td align="left">32.7</td></tr>
###xml 1264 1269 1264 1269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Male</td>
###xml 1269 1271 1269 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">76</td>
###xml 1271 1275 1271 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67.3</td>
###xml 1264 1275 1264 1275 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Male</td><td align="left">76</td><td align="left">67.3</td></tr>
###xml 1275 1284 1275 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Histology</td>
###xml 1275 1284 1275 1284 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Histology</td></tr>
###xml 1284 1308 1284 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Squamous cell carcinoma</td>
###xml 1308 1310 1308 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30</td>
###xml 1310 1314 1310 1314 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.5</td>
###xml 1284 1314 1284 1314 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Squamous cell carcinoma</td><td align="left">30</td><td align="left">26.5</td></tr>
###xml 1314 1329 1314 1329 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Adenocarcinoma</td>
###xml 1329 1331 1329 1331 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">80</td>
###xml 1331 1335 1331 1335 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70.8</td>
###xml 1314 1335 1314 1335 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Adenocarcinoma</td><td align="left">80</td><td align="left">70.8</td></tr>
###xml 1335 1377 1335 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Large cell and undifferentiated carcinoma</td>
###xml 1377 1378 1377 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1378 1381 1378 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.7</td>
###xml 1335 1381 1335 1381 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Large cell and undifferentiated carcinoma</td><td align="left">3</td><td align="left">2.7</td></tr>
###xml 1381 1402 1381 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Chemotherapy regimens</td>
###xml 1381 1402 1381 1402 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Chemotherapy regimens</td></tr>
###xml 1402 1422 1402 1422 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DDP/CBP+TAX/TXT/DOC</td>
###xml 1422 1424 1422 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49</td>
###xml 1424 1428 1424 1428 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">43.4</td>
###xml 1402 1428 1402 1428 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DDP/CBP+TAX/TXT/DOC</td><td align="left">49</td><td align="left">43.4</td></tr>
###xml 1428 1440 1428 1440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DDP/CBP+GEM</td>
###xml 1440 1442 1440 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">59</td>
###xml 1442 1446 1442 1446 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52.2</td>
###xml 1428 1446 1428 1446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DDP/CBP+GEM</td><td align="left">59</td><td align="left">52.2</td></tr>
###xml 1446 1458 1446 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;DDP/CBP+NVB</td>
###xml 1458 1459 1458 1459 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 1459 1462 1459 1462 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.4</td>
###xml 1446 1462 1446 1462 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;DDP/CBP+NVB</td><td align="left">5</td><td align="left">4.4</td></tr>
###xml 1207 1462 1207 1462 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="3">Age (years)</td></tr><tr><td align="left">&#160;Median (range)</td><td align="left">59.6 (34-84)</td><td align="left"/></tr><tr><td align="left" colspan="3">Gender</td></tr><tr><td align="left">&#160;Female</td><td align="left">37</td><td align="left">32.7</td></tr><tr><td align="left">&#160;Male</td><td align="left">76</td><td align="left">67.3</td></tr><tr><td align="left" colspan="3">Histology</td></tr><tr><td align="left">&#160;Squamous cell carcinoma</td><td align="left">30</td><td align="left">26.5</td></tr><tr><td align="left">&#160;Adenocarcinoma</td><td align="left">80</td><td align="left">70.8</td></tr><tr><td align="left">&#160;Large cell and undifferentiated carcinoma</td><td align="left">3</td><td align="left">2.7</td></tr><tr><td align="left" colspan="3">Chemotherapy regimens</td></tr><tr><td align="left">&#160;DDP/CBP+TAX/TXT/DOC</td><td align="left">49</td><td align="left">43.4</td></tr><tr><td align="left">&#160;DDP/CBP+GEM</td><td align="left">59</td><td align="left">52.2</td></tr><tr><td align="left">&#160;DDP/CBP+NVB</td><td align="left">5</td><td align="left">4.4</td></tr></tbody>
###xml 1178 1462 1178 1462 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Patient no.</th><th align="left">(%)</th></tr></thead><tbody><tr><td align="left" colspan="3">Age (years)</td></tr><tr><td align="left">&#160;Median (range)</td><td align="left">59.6 (34-84)</td><td align="left"/></tr><tr><td align="left" colspan="3">Gender</td></tr><tr><td align="left">&#160;Female</td><td align="left">37</td><td align="left">32.7</td></tr><tr><td align="left">&#160;Male</td><td align="left">76</td><td align="left">67.3</td></tr><tr><td align="left" colspan="3">Histology</td></tr><tr><td align="left">&#160;Squamous cell carcinoma</td><td align="left">30</td><td align="left">26.5</td></tr><tr><td align="left">&#160;Adenocarcinoma</td><td align="left">80</td><td align="left">70.8</td></tr><tr><td align="left">&#160;Large cell and undifferentiated carcinoma</td><td align="left">3</td><td align="left">2.7</td></tr><tr><td align="left" colspan="3">Chemotherapy regimens</td></tr><tr><td align="left">&#160;DDP/CBP+TAX/TXT/DOC</td><td align="left">49</td><td align="left">43.4</td></tr><tr><td align="left">&#160;DDP/CBP+GEM</td><td align="left">59</td><td align="left">52.2</td></tr><tr><td align="left">&#160;DDP/CBP+NVB</td><td align="left">5</td><td align="left">4.4</td></tr></tbody></table>
###xml 1462 1465 1462 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDP</italic>
###xml 1477 1480 1477 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 1494 1497 1494 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAX</italic>
###xml 1516 1519 1516 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TXT</italic>
###xml 1530 1533 1530 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DOC</italic>
###xml 1545 1548 1545 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GEM</italic>
###xml 1562 1565 1562 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NVB</italic>
###xml 1462 1577 1462 1577 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23"><italic>DDP</italic> cisplatin, <italic>CBP</italic> carboplatin, <italic>TAX</italic> taxol/paclitaxel, <italic>TXT</italic> taxetere, <italic>DOC</italic> docetaxel, <italic>GEM</italic> gemcitabine, <italic>NVB</italic> vinorelbine</p>
###xml 1462 1577 1462 1577 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23"><italic>DDP</italic> cisplatin, <italic>CBP</italic> carboplatin, <italic>TAX</italic> taxol/paclitaxel, <italic>TXT</italic> taxetere, <italic>DOC</italic> docetaxel, <italic>GEM</italic> gemcitabine, <italic>NVB</italic> vinorelbine</p></table-wrap-foot>
###xml 1104 1577 1104 1577 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="22">Patient clinicopathologic characteristics and chemotherapy regimens</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Patient no.</th><th align="left">(%)</th></tr></thead><tbody><tr><td align="left" colspan="3">Age (years)</td></tr><tr><td align="left">&#160;Median (range)</td><td align="left">59.6 (34-84)</td><td align="left"/></tr><tr><td align="left" colspan="3">Gender</td></tr><tr><td align="left">&#160;Female</td><td align="left">37</td><td align="left">32.7</td></tr><tr><td align="left">&#160;Male</td><td align="left">76</td><td align="left">67.3</td></tr><tr><td align="left" colspan="3">Histology</td></tr><tr><td align="left">&#160;Squamous cell carcinoma</td><td align="left">30</td><td align="left">26.5</td></tr><tr><td align="left">&#160;Adenocarcinoma</td><td align="left">80</td><td align="left">70.8</td></tr><tr><td align="left">&#160;Large cell and undifferentiated carcinoma</td><td align="left">3</td><td align="left">2.7</td></tr><tr><td align="left" colspan="3">Chemotherapy regimens</td></tr><tr><td align="left">&#160;DDP/CBP+TAX/TXT/DOC</td><td align="left">49</td><td align="left">43.4</td></tr><tr><td align="left">&#160;DDP/CBP+GEM</td><td align="left">59</td><td align="left">52.2</td></tr><tr><td align="left">&#160;DDP/CBP+NVB</td><td align="left">5</td><td align="left">4.4</td></tr></tbody></table><table-wrap-foot><p textid="23"><italic>DDP</italic> cisplatin, <italic>CBP</italic> carboplatin, <italic>TAX</italic> taxol/paclitaxel, <italic>TXT</italic> taxetere, <italic>DOC</italic> docetaxel, <italic>GEM</italic> gemcitabine, <italic>NVB</italic> vinorelbine</p></table-wrap-foot></table-wrap>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 618 624 <span type="species:ncbi:9606">people</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
###xml 1007 1015 <span type="species:ncbi:9606">patients</span>
###xml 1073 1081 <span type="species:ncbi:9606">patients</span>
All patients for the study were recruited from several hospitals in Nanjing of China between March 2006 and September 2007. To avoid the confounding effect of differences in outcome resulting from clinical stage, only advanced NSCLC patients were included in the analysis. Because SNPs evaluated in the present study are potentially relevant to therapies based on platinum, only the response to the first platinum-based regimen was assessed, and the patients who had received previous chemotherapy were excluded. There were 113 patients who were eligible in this study. These 113 eligible patients, all of Chinese Han people, were diagnosed with histologically confirmed advanced NSCLC (stages IIIA-IV), and had a measurable lesion by CT scan, a Karnofsky performance status of not less than 60. The status of all patients in electrocardiogram, blood chemistries, hepatic, and renal function at the beginning of treatment was normal. The study was approved by an Ethics Review Committee at the hospital and patients gave consent to participate. The main characteristics of patients were shown in Table 1.Table 1Patient clinicopathologic characteristics and chemotherapy regimensCharacteristicsPatient no.(%)Age (years) Median (range)59.6 (34-84)Gender Female3732.7 Male7667.3Histology Squamous cell carcinoma3026.5 Adenocarcinoma8070.8 Large cell and undifferentiated carcinoma32.7Chemotherapy regimens DDP/CBP+TAX/TXT/DOC4943.4 DDP/CBP+GEM5952.2 DDP/CBP+NVB54.4DDP cisplatin, CBP carboplatin, TAX taxol/paclitaxel, TXT taxetere, DOC docetaxel, GEM gemcitabine, NVB vinorelbine
###end p 21
###begin p 22
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient clinicopathologic characteristics and chemotherapy regimens
###end p 22
###begin p 23
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDP</italic>
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAX</italic>
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TXT</italic>
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DOC</italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GEM</italic>
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NVB</italic>
DDP cisplatin, CBP carboplatin, TAX taxol/paclitaxel, TXT taxetere, DOC docetaxel, GEM gemcitabine, NVB vinorelbine
###end p 23
###begin title 24
Chemotherapy regimens and therapeutic effect evaluation
###end title 24
###begin p 25
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 515 516 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 650 657 <span type="species:ncbi:9606">Patient</span>
###xml 1015 1023 <span type="species:ncbi:9606">Patients</span>
###xml 1146 1154 <span type="species:ncbi:9606">patients</span>
All patients had received platinum-based chemotherapy, 49 (43.4%) were given TP/TC/DP/DC regimens (DDP/CBP+TAX/TXT/DOC), 59 (52.2%) had GP/GC regimens (DDP/CBP+GEM), and 5 (4.4%) received NP/NC regimens (DDP/CBP+NVB) (Table 1). Concrete dosage: DDP (cisplatin) 30 mg/m2 on day 2-4; CBP (carboplatin) AUC = 4-5 g on day 1; TAX (taxol/paclitaxel) 175 mg/m2 on day 1 (kept for 3 h), TXT (taxetere)/DOC (docetaxel) 75 mg/m2 on day 1 (kept for 1 h); GEM (gemcitabine) 1 g/m2 on day 1 and day 8; NVB (vinorelbine) 25 mg/m2 on days 1 and 8. All chemotherapeutic drugs were administered intravenously, and the treatment cycles were repeated every 3-4 weeks. Patient responses to treatment were determined after four cycles by the WHO criteria [22], which classify the response into four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). CR was defined as complete disappearance of all measurable lesions. PR required at least 50% reduction in measurable lesions. Patients with SD had less than a 50% decrease or no more than a 25% increase in the size of measurable lesions. PD was assigned to patients when measurable lesions increased by more than 25% or new lesions appeared. For data analysis, CR and PR were combined as responders, and SD and PD were grouped as non-responders.
###end p 25
###begin title 26
DNA collection and genotyping
###end title 26
###begin p 27
###xml 5 12 <span type="species:ncbi:9606">patient</span>
Each patient provided 5 ml pretreatment blood for the study. The blood samples were collected in citric acid/EDTA anticoagulation tubes and stored at -80degreesC until analysis. Genomic DNA was isolated from the blood samples using QIAGEN DNA mini Kit (China), and stored at 4degreesC until use.
###end p 27
###begin p 28
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 894 895 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 895 896 867 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 990 997 950 957 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 997 1028 957 988 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Sequences of primers and probes</p>
###xml 997 1028 957 988 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Sequences of primers and probes</p></caption>
###xml 1028 1033 988 993 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus</th>
###xml 1033 1051 993 1011 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Primers and probes</th>
###xml 1028 1051 988 1011 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Locus</th><th align="left">Primers and probes</th></tr>
###xml 1028 1051 988 1011 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Locus</th><th align="left">Primers and probes</th></tr></thead>
###xml 1051 1055 1011 1015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MRP2</td>
###xml 1055 1097 1015 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Forward primer: 5&#8242;-CCTTTACGGAGAACATCAGA-3&#8242;</td>
###xml 1051 1097 1011 1057 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">MRP2</td><td align="left">Forward primer: 5&#8242;-CCTTTACGGAGAACATCAGA-3&#8242;</td></tr>
###xml 1097 1114 1057 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">(C-24T, rs717620)</td>
###xml 1114 1175 1074 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-TTTGCATTACATTTCCCAGA-3&#8242;</td>
###xml 1097 1175 1057 1126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">(C-24T, rs717620)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-TTTGCATTACATTTCCCAGA-3&#8242;</td></tr>
###xml 1175 1205 1126 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Probe: 5&#8242;-Cy3-AGTCTTCGTTCCA-3&#8242;</td>
###xml 1175 1205 1126 1156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Probe: 5&#8242;-Cy3-AGTCTTCGTTCCA-3&#8242;</td></tr>
###xml 1205 1229 1156 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> 5&#8242;-Cy5-AGTCTTTGTTCCA-3&#8242;</td>
###xml 1205 1229 1156 1180 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> 5&#8242;-Cy5-AGTCTTTGTTCCA-3&#8242;</td></tr>
###xml 1229 1247 1180 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MRP2 (Val 417 Ile)</td>
###xml 1247 1289 1198 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Forward primer: 5&#8242;-TGGAGGCAAGAAGTCACAGT-3&#8242;</td>
###xml 1229 1289 1180 1240 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">MRP2 (Val 417 Ile)</td><td align="left">Forward primer: 5&#8242;-TGGAGGCAAGAAGTCACAGT-3&#8242;</td></tr>
###xml 1289 1308 1240 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">(G1249A, rs2273697)</td>
###xml 1308 1369 1259 1311 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-GATTACAAGCACCATCACCC-3&#8242;</td>
###xml 1289 1369 1240 1311 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">(G1249A, rs2273697)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-GATTACAAGCACCATCACCC-3&#8242;</td></tr>
###xml 1369 1399 1311 1341 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Probe: 5&#8242;-Cy3-TACACCGTTGGAG-3&#8242;</td>
###xml 1369 1399 1311 1341 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Probe: 5&#8242;-Cy3-TACACCGTTGGAG-3&#8242;</td></tr>
###xml 1399 1423 1341 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> 5&#8242;-Cy5-TACACCATTGGAG-3&#8242;</td>
###xml 1399 1423 1341 1365 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> 5&#8242;-Cy5-TACACCATTGGAG-3&#8242;</td></tr>
###xml 1423 1443 1365 1385 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MRP2 (Ile 1,324 Ile)</td>
###xml 1443 1506 1385 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Forward primer: 5&#8242;-Acrydite&#8482;-CACTGCTACCCTTCTCCTGTTC-3&#8242;</td>
###xml 1423 1506 1365 1439 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">MRP2 (Ile 1,324 Ile)</td><td align="left">Forward primer: 5&#8242;-Acrydite&#8482;-CACTGCTACCCTTCTCCTGTTC-3&#8242;</td></tr>
###xml 1506 1525 1439 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">(C3972T, rs3740066)</td>
###xml 1525 1567 1458 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reverse primer: 5&#8242;-CTGACCCTTTCCCTCCATCC-3&#8242;</td>
###xml 1506 1567 1439 1500 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">(C3972T, rs3740066)</td><td align="left">Reverse primer: 5&#8242;-CTGACCCTTTCCCTCCATCC-3&#8242;</td></tr>
###xml 1567 1597 1500 1530 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Probe: 5&#8242;-Cy3-GCTACCGATGTCA-3&#8242;</td>
###xml 1567 1597 1500 1530 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Probe: 5&#8242;-Cy3-GCTACCGATGTCA-3&#8242;</td></tr>
###xml 1597 1621 1530 1554 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> 5&#8242;-Cy5-GCTACCAATGTCA-3&#8242;</td>
###xml 1597 1621 1530 1554 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> 5&#8242;-Cy5-GCTACCAATGTCA-3&#8242;</td></tr>
###xml 1621 1640 1554 1573 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GSTP1 (Ile 105 Val)</td>
###xml 1640 1682 1573 1615 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Forward primer: 5&#8242;-CAGGGCTCTATGGGAAGGAC-3&#8242;</td>
###xml 1621 1682 1554 1615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GSTP1 (Ile 105 Val)</td><td align="left">Forward primer: 5&#8242;-CAGGGCTCTATGGGAAGGAC-3&#8242;</td></tr>
###xml 1682 1697 1615 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">(A342G, rs1695)</td>
###xml 1697 1761 1630 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-CAGGAGATCAGAAACCACCAGTT-3&#8242;</td>
###xml 1682 1761 1615 1685 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">(A342G, rs1695)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-CAGGAGATCAGAAACCACCAGTT-3&#8242;</td></tr>
###xml 1761 1791 1685 1715 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Probe: 5&#8242;-Cy3-AAATACATCTCCC-3&#8242;</td>
###xml 1761 1791 1685 1715 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Probe: 5&#8242;-Cy3-AAATACATCTCCC-3&#8242;</td></tr>
###xml 1791 1815 1715 1739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> 5&#8242;-Cy5-AAATACGTCTCCC-3&#8242;</td>
###xml 1791 1815 1715 1739 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> 5&#8242;-Cy5-AAATACGTCTCCC-3&#8242;</td></tr>
###xml 1051 1815 1011 1739 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">MRP2</td><td align="left">Forward primer: 5&#8242;-CCTTTACGGAGAACATCAGA-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C-24T, rs717620)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-TTTGCATTACATTTCCCAGA-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AGTCTTCGTTCCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AGTCTTTGTTCCA-3&#8242;</td></tr><tr><td align="left">MRP2 (Val 417 Ile)</td><td align="left">Forward primer: 5&#8242;-TGGAGGCAAGAAGTCACAGT-3&#8242;</td></tr><tr><td align="left" rowspan="3">(G1249A, rs2273697)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-GATTACAAGCACCATCACCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-TACACCGTTGGAG-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-TACACCATTGGAG-3&#8242;</td></tr><tr><td align="left">MRP2 (Ile 1,324 Ile)</td><td align="left">Forward primer: 5&#8242;-Acrydite&#8482;-CACTGCTACCCTTCTCCTGTTC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C3972T, rs3740066)</td><td align="left">Reverse primer: 5&#8242;-CTGACCCTTTCCCTCCATCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-GCTACCGATGTCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-GCTACCAATGTCA-3&#8242;</td></tr><tr><td align="left">GSTP1 (Ile 105 Val)</td><td align="left">Forward primer: 5&#8242;-CAGGGCTCTATGGGAAGGAC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(A342G, rs1695)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-CAGGAGATCAGAAACCACCAGTT-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AAATACATCTCCC-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AAATACGTCTCCC-3&#8242;</td></tr></tbody>
###xml 1028 1815 988 1739 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Primers and probes</th></tr></thead><tbody><tr><td align="left">MRP2</td><td align="left">Forward primer: 5&#8242;-CCTTTACGGAGAACATCAGA-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C-24T, rs717620)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-TTTGCATTACATTTCCCAGA-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AGTCTTCGTTCCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AGTCTTTGTTCCA-3&#8242;</td></tr><tr><td align="left">MRP2 (Val 417 Ile)</td><td align="left">Forward primer: 5&#8242;-TGGAGGCAAGAAGTCACAGT-3&#8242;</td></tr><tr><td align="left" rowspan="3">(G1249A, rs2273697)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-GATTACAAGCACCATCACCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-TACACCGTTGGAG-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-TACACCATTGGAG-3&#8242;</td></tr><tr><td align="left">MRP2 (Ile 1,324 Ile)</td><td align="left">Forward primer: 5&#8242;-Acrydite&#8482;-CACTGCTACCCTTCTCCTGTTC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C3972T, rs3740066)</td><td align="left">Reverse primer: 5&#8242;-CTGACCCTTTCCCTCCATCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-GCTACCGATGTCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-GCTACCAATGTCA-3&#8242;</td></tr><tr><td align="left">GSTP1 (Ile 105 Val)</td><td align="left">Forward primer: 5&#8242;-CAGGGCTCTATGGGAAGGAC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(A342G, rs1695)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-CAGGAGATCAGAAACCACCAGTT-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AAATACATCTCCC-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AAATACGTCTCCC-3&#8242;</td></tr></tbody></table>
###xml 990 1815 950 1739 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="29">Sequences of primers and probes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Primers and probes</th></tr></thead><tbody><tr><td align="left">MRP2</td><td align="left">Forward primer: 5&#8242;-CCTTTACGGAGAACATCAGA-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C-24T, rs717620)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-TTTGCATTACATTTCCCAGA-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AGTCTTCGTTCCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AGTCTTTGTTCCA-3&#8242;</td></tr><tr><td align="left">MRP2 (Val 417 Ile)</td><td align="left">Forward primer: 5&#8242;-TGGAGGCAAGAAGTCACAGT-3&#8242;</td></tr><tr><td align="left" rowspan="3">(G1249A, rs2273697)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-GATTACAAGCACCATCACCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-TACACCGTTGGAG-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-TACACCATTGGAG-3&#8242;</td></tr><tr><td align="left">MRP2 (Ile 1,324 Ile)</td><td align="left">Forward primer: 5&#8242;-Acrydite&#8482;-CACTGCTACCCTTCTCCTGTTC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(C3972T, rs3740066)</td><td align="left">Reverse primer: 5&#8242;-CTGACCCTTTCCCTCCATCC-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-GCTACCGATGTCA-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-GCTACCAATGTCA-3&#8242;</td></tr><tr><td align="left">GSTP1 (Ile 105 Val)</td><td align="left">Forward primer: 5&#8242;-CAGGGCTCTATGGGAAGGAC-3&#8242;</td></tr><tr><td align="left" rowspan="3">(A342G, rs1695)</td><td align="left">Reverse primer: 5&#8242;-Acrydite&#8482;-CAGGAGATCAGAAACCACCAGTT-3&#8242;</td></tr><tr><td align="left">Probe: 5&#8242;-Cy3-AAATACATCTCCC-3&#8242;</td></tr><tr><td align="left"> 5&#8242;-Cy5-AAATACGTCTCCC-3&#8242;</td></tr></tbody></table></table-wrap>
Single-nucleotide polymorphisms were analyzed with a 3-D polyacrylamide gel-based DNA microarray genotyping method. This method was invented by researchers of State Key Laboratory of Bioelectronics, Southeast University in 2005 (Patent code: 200510040597.3) [23]. Probes and primers were designed by Primer Premier 5.0 Software. The sequences of primers and probes are shown in Table 2. One of each pair primers was modified with acrylamide phosphoramidite (Acryditetrade mark; Matrix Technologies) at its 5'-terminal. Each couple of probes was labeled with Cy3 and Cy5 fluorescent dyes at 5'-terminal respectively. The PCR reactions were performed in 30 mul reaction solution containing 10 pmol primer and 50 ng genomic DNA. The PCR reaction consisted of an initial step at 95degreesC for 5 min, then 35-40 cycles of denaturing at 94degreesC for 30 s, annealing at 48-60degreesC (according to Tm) for 30 s and extension at 72degreesC for 40 s, and a last extension at 72degreesC for 5 min.Table 2Sequences of primers and probesLocusPrimers and probesMRP2Forward primer: 5'-CCTTTACGGAGAACATCAGA-3'(C-24T, rs717620)Reverse primer: 5'-Acryditetrade mark-TTTGCATTACATTTCCCAGA-3'Probe: 5'-Cy3-AGTCTTCGTTCCA-3' 5'-Cy5-AGTCTTTGTTCCA-3'MRP2 (Val 417 Ile)Forward primer: 5'-TGGAGGCAAGAAGTCACAGT-3'(G1249A, rs2273697)Reverse primer: 5'-Acryditetrade mark-GATTACAAGCACCATCACCC-3'Probe: 5'-Cy3-TACACCGTTGGAG-3' 5'-Cy5-TACACCATTGGAG-3'MRP2 (Ile 1,324 Ile)Forward primer: 5'-Acryditetrade mark-CACTGCTACCCTTCTCCTGTTC-3'(C3972T, rs3740066)Reverse primer: 5'-CTGACCCTTTCCCTCCATCC-3'Probe: 5'-Cy3-GCTACCGATGTCA-3' 5'-Cy5-GCTACCAATGTCA-3'GSTP1 (Ile 105 Val)Forward primer: 5'-CAGGGCTCTATGGGAAGGAC-3'(A342G, rs1695)Reverse primer: 5'-Acryditetrade mark-CAGGAGATCAGAAACCACCAGTT-3'Probe: 5'-Cy3-AAATACATCTCCC-3' 5'-Cy5-AAATACGTCTCCC-3'
###end p 28
###begin p 29
Sequences of primers and probes
###end p 29
###begin p 30
After PCR amplification and gel electrophoresis test, PCR products were processed by ethanol precipitation, evaporation, or left untreated. Solutions containing acrylamide-modified PCR products, glycerol, ammonium persulfate (APS), and acrylamide monomers were prepared, spotted, and polymerized onto the acryl-modified slide. In the process, TEMED is introduced onto the spotted microarray to immobilize the modified nucleic acids. Following the attachment to obtain ssDNA for hybridization analysis, dsDNA on the slides was denatured in 0.1 M NaOH for 10 min. After hybridization, the slide was subjected to electrophoresis under 5-30 V/cm for 5-20 min in 1x Tris-Borate-EDTA (TBE) buffer at 4degreesC. Images of the slides were captured by a scanner (LuxScantrade mark-10 K Confocal Scanner, Packard BioScience Company, USA) and were analyzed with Genepix Pro 3.0 Software. Sequencing of 10% samples was performed to validate the results.
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 229 230 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 240 241 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 487 488 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 550 551 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1110 1111 1106 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1148 1149 1144 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 757 764 <span type="species:ncbi:9606">patient</span>
###xml 980 987 <span type="species:ncbi:9606">patient</span>
###xml 1011 1019 <span type="species:ncbi:9606">patients</span>
Statistical analysis was performed using SPSS Software Package Version 13.0 (SPSS Inc., Chicago, IL, USA). The significance of differences in frequencies and genotypes between good and poor responders was calculated using the chi2 test. chi2 test was also performed to test for Hardy-Weinberg equilibrium (HWE), haplotype frequencies and haplotype-trait association. Continuity correction test or Fisher's exact test was performed when >20% cells have expected count <5, but not <1, and n > 40, or when theoretical frequency had expected count <1 or n < 40. Multivariate analyses were performed with the use of unconditional logistic regression analysis to assess the association between treatment response and each genetic polymorphism while adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens. The logistic regression model was used to calculate the OR and their 95% CI. In the regression analysis, the outcome variable was patient response to treatment; patients who had poor respond to treatment (SD+PD) were compared with good responders (CR+PR). All P values reported were two-sided, and P values <0.05 were considered statistically significant.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Images of DNA-microarray hybridization for SNPs genotyping
###end title 34
###begin p 35
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 358 364 358 364 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 555 558 555 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 621 622 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 664 665 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 670 671 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 676 677 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 901 902 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 970 971 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1018 1023 1018 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spots</italic>
###xml 1037 1038 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1052 1053 1052 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 364 1085 364 1085 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Microarray hybridization scanning patterns of SNPs genotyping. <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> the microarray images of locus MRP2 C-24T, MRP2 Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; <italic>green</italic>, <italic>yellow</italic> and <italic>red</italic> represent wild, hybrid and mutation type, respectively. <italic>a</italic>, <italic>b</italic>, <italic>c</italic> and <italic>d</italic> the corresponding scatter plots of <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> showing the genotype assignment. Each scatter spot shows the signal intensities from each sample without correction for the average local background signal from the microarrays. The scatter spots close to the longitudinal (<italic>y</italic>) axis indicate the wild homozygote and those close to the lateral (<italic>x</italic>) axis indicate the mutational homozygote. The <italic>spots</italic> far from the <italic>x</italic> axis and the <italic>y</italic> axis indicated the heterozygote</p>
###xml 364 1085 364 1085 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Microarray hybridization scanning patterns of SNPs genotyping. <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> the microarray images of locus MRP2 C-24T, MRP2 Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; <italic>green</italic>, <italic>yellow</italic> and <italic>red</italic> represent wild, hybrid and mutation type, respectively. <italic>a</italic>, <italic>b</italic>, <italic>c</italic> and <italic>d</italic> the corresponding scatter plots of <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> showing the genotype assignment. Each scatter spot shows the signal intensities from each sample without correction for the average local background signal from the microarrays. The scatter spots close to the longitudinal (<italic>y</italic>) axis indicate the wild homozygote and those close to the lateral (<italic>x</italic>) axis indicate the mutational homozygote. The <italic>spots</italic> far from the <italic>x</italic> axis and the <italic>y</italic> axis indicated the heterozygote</p></caption>
###xml 1085 1085 1085 1085 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2009_1046_Fig1_HTML" id="MO1"/>
###xml 358 1085 358 1085 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="36">Microarray hybridization scanning patterns of SNPs genotyping. <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> the microarray images of locus MRP2 C-24T, MRP2 Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; <italic>green</italic>, <italic>yellow</italic> and <italic>red</italic> represent wild, hybrid and mutation type, respectively. <italic>a</italic>, <italic>b</italic>, <italic>c</italic> and <italic>d</italic> the corresponding scatter plots of <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>D</italic> showing the genotype assignment. Each scatter spot shows the signal intensities from each sample without correction for the average local background signal from the microarrays. The scatter spots close to the longitudinal (<italic>y</italic>) axis indicate the wild homozygote and those close to the lateral (<italic>x</italic>) axis indicate the mutational homozygote. The <italic>spots</italic> far from the <italic>x</italic> axis and the <italic>y</italic> axis indicated the heterozygote</p></caption><graphic position="anchor" xlink:href="280_2009_1046_Fig1_HTML" id="MO1"/></fig>
On the basis of the immobilization efficiency, acryl-modified glass slides were selected to fabricate DNA microarrays. By allele-specific oligonucleotide dual-color fluorescence hybridization, homozygous wild type, homozygous mutant type, and heterozygote type yielded green, red, and yellow fluorescence, respectively. Figure 1 showed the microarray images.Fig. 1Microarray hybridization scanning patterns of SNPs genotyping. A, B, C and D the microarray images of locus MRP2 C-24T, MRP2 Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; green, yellow and red represent wild, hybrid and mutation type, respectively. a, b, c and d the corresponding scatter plots of A, B, C and D showing the genotype assignment. Each scatter spot shows the signal intensities from each sample without correction for the average local background signal from the microarrays. The scatter spots close to the longitudinal (y) axis indicate the wild homozygote and those close to the lateral (x) axis indicate the mutational homozygote. The spots far from the x axis and the y axis indicated the heterozygote
###end p 35
###begin p 36
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 300 301 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 654 659 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spots</italic>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
Microarray hybridization scanning patterns of SNPs genotyping. A, B, C and D the microarray images of locus MRP2 C-24T, MRP2 Val417Ile, MRP2 Ile1324Ile and GSTP1 Ile105Val; green, yellow and red represent wild, hybrid and mutation type, respectively. a, b, c and d the corresponding scatter plots of A, B, C and D showing the genotype assignment. Each scatter spot shows the signal intensities from each sample without correction for the average local background signal from the microarrays. The scatter spots close to the longitudinal (y) axis indicate the wild homozygote and those close to the lateral (x) axis indicate the mutational homozygote. The spots far from the x axis and the y axis indicated the heterozygote
###end p 36
###begin title 37
Sequencing result
###end title 37
###begin p 38
Sequencing of 10% samples randomly selected was performed. The result was 100% concordance to that of the genotyping suggesting that the 3-D DNA microarray method is reliable.
###end p 38
###begin title 39
Treatment response and genotype
###end title 39
###begin p 40
###xml 7 15 <span type="species:ncbi:9606">patients</span>
Of 113 patients, 30 (26.5%) had some responses (CR+PR) and 83 (73.5%) showed no response (SD+PD).
###end p 40
###begin p 41
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">5</xref>
###xml 1143 1144 1143 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1184 1185 1184 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1318 1319 1318 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab6" ref-type="table">6</xref>
###xml 1456 1457 1456 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1673 1680 1673 1680 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1740 1741 1740 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1680 1748 1680 1748 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Genotype and response to chemotherapy among NSCLC patients (<italic>n</italic>&#160;=&#160;113)</p>
###xml 1680 1748 1680 1748 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Genotype and response to chemotherapy among NSCLC patients (<italic>n</italic>&#160;=&#160;113)</p></caption>
###xml 1748 1756 1748 1756 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Genotype</th>
###xml 1756 1761 1756 1761 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Cases</th>
###xml 1761 1785 1761 1785 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Response to chemotherapy</th>
###xml 1785 1796 1785 1796 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">OR (95% CI)</th>
###xml 1796 1797 1796 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1796 1803 1796 1803 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>P</italic> value</th>
###xml 1803 1823 1803 1823 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Adjusted OR (95% CI)</th>
###xml 1832 1833 1832 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1823 1839 1823 1839 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Adjusted <italic>P</italic> value</th>
###xml 1748 1839 1748 1839 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Genotype</th><th align="left" rowspan="2">Cases</th><th align="left" colspan="2">Response to chemotherapy</th><th align="left" rowspan="2">OR (95% CI)</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Adjusted OR (95% CI)</th><th align="left" rowspan="2">Adjusted <italic>P</italic> value</th></tr>
###xml 1851 1852 1851 1852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1839 1857 1839 1857 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CR&#160;+&#160;PR (%) <italic>n</italic>&#160;=&#160;30</th>
###xml 1869 1870 1869 1870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1857 1875 1857 1875 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SD&#160;+&#160;PD (%) <italic>n</italic>&#160;=&#160;83</th>
###xml 1839 1875 1839 1875 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">CR&#160;+&#160;PR (%) <italic>n</italic>&#160;=&#160;30</th><th align="left">SD&#160;+&#160;PD (%) <italic>n</italic>&#160;=&#160;83</th></tr>
###xml 1748 1875 1748 1875 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Genotype</th><th align="left" rowspan="2">Cases</th><th align="left" colspan="2">Response to chemotherapy</th><th align="left" rowspan="2">OR (95% CI)</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Adjusted OR (95% CI)</th><th align="left" rowspan="2">Adjusted <italic>P</italic> value</th></tr><tr><th align="left">CR&#160;+&#160;PR (%) <italic>n</italic>&#160;=&#160;30</th><th align="left">SD&#160;+&#160;PD (%) <italic>n</italic>&#160;=&#160;83</th></tr></thead>
###xml 1875 1887 1875 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">MRP2 (C-24T)</td>
###xml 1875 1887 1875 1887 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">MRP2 (C-24T)</td></tr>
###xml 1887 1891 1887 1891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/C</td>
###xml 1891 1893 1891 1893 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">66</td>
###xml 1893 1902 1893 1902 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11 (36.7)</td>
###xml 1902 1911 1902 1911 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">55 (66.3)</td>
###xml 1911 1912 1911 1912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 1912 1917 1912 1917 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.015</td>
###xml 1917 1937 1917 1937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.069 (1.518&#8211;10.910)</td>
###xml 1937 1942 1937 1942 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.005</td>
###xml 1887 1942 1887 1942 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/C</td><td char="." align="char">66</td><td align="left">11 (36.7)</td><td align="left">55 (66.3)</td><td align="left">1</td><td align="left">0.015</td><td align="left">4.069 (1.518&#8211;10.910)</td><td align="left">0.005</td></tr>
###xml 1942 1946 1942 1946 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/T</td>
###xml 1946 1948 1946 1948 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43</td>
###xml 1948 1957 1948 1957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16 (53.3)</td>
###xml 1957 1966 1957 1966 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27 (32.5)</td>
###xml 1966 1985 1966 1985 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.959 (1.211&#8211;7.246)</td>
###xml 1985 1990 1985 1990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.023</td>
###xml 1990 2012 1990 2012 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10.514 (0.842&#8211;131.319)</td>
###xml 2012 2017 2012 2017 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.068</td>
###xml 1942 2017 1942 2017 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/T</td><td char="." align="char">43</td><td align="left">16 (53.3)</td><td align="left">27 (32.5)</td><td align="left">2.959 (1.211&#8211;7.246)</td><td align="left">0.023</td><td align="left">10.514 (0.842&#8211;131.319)</td><td align="left">0.068</td></tr>
###xml 2017 2021 2017 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;T/T</td>
###xml 2021 2022 2021 2022 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2022 2030 2022 2030 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3 (10.0)</td>
###xml 2030 2037 2030 2037 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1 (1.2)</td>
###xml 2037 2059 2037 2059 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">14.925 (1.425&#8211;166.667)</td>
###xml 2059 2064 2059 2064 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.005</td>
###xml 2064 2084 2064 2084 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.493 (1.728&#8211;11.682)</td>
###xml 2084 2089 2084 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.002</td>
###xml 2017 2089 2017 2089 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;T/T</td><td char="." align="char">4</td><td align="left">3 (10.0)</td><td align="left">1 (1.2)</td><td align="left">14.925 (1.425&#8211;166.667)</td><td align="left">0.005</td><td align="left">4.493 (1.728&#8211;11.682)</td><td align="left">0.002</td></tr>
###xml 2089 2097 2089 2097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/T+T/T</td>
###xml 2097 2099 2097 2099 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47</td>
###xml 2099 2108 2099 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">19 (63.3)</td>
###xml 2108 2117 2108 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28 (33.7)</td>
###xml 2117 2136 2117 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.390 (1.420&#8211;8.130)</td>
###xml 2136 2136 2136 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2136 2136 2136 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2136 2136 2136 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2089 2136 2089 2136 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/T+T/T</td><td char="." align="char">47</td><td align="left">19 (63.3)</td><td align="left">28 (33.7)</td><td align="left">3.390 (1.420&#8211;8.130)</td><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 2136 2152 2136 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">MRP2 (Val417Ile)</td>
###xml 2136 2152 2136 2152 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">MRP2 (Val417Ile)</td></tr>
###xml 2152 2156 2152 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;G/G</td>
###xml 2156 2158 2156 2158 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">84</td>
###xml 2158 2167 2158 2167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">20 (66.7)</td>
###xml 2167 2176 2167 2176 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64 (77.1)</td>
###xml 2176 2177 2176 2177 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 2177 2177 2177 2177 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2177 2177 2177 2177 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2177 2177 2177 2177 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2152 2177 2152 2177 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;G/G</td><td char="." align="char">84</td><td align="left">20 (66.7)</td><td align="left">64 (77.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 2177 2181 2177 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;G/A</td>
###xml 2181 2183 2181 2183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 2183 2191 2183 2191 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9 (30.0)</td>
###xml 2191 2200 2191 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17 (20.5)</td>
###xml 2200 2219 2200 2219 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.695 (0.654&#8211;4.386)</td>
###xml 2219 2224 2219 2224 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.274</td>
###xml 2224 2243 2224 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.910 (0.697&#8211;5.229)</td>
###xml 2243 2248 2243 2248 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.208</td>
###xml 2177 2248 2177 2248 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;G/A</td><td char="." align="char">26</td><td align="left">9 (30.0)</td><td align="left">17 (20.5)</td><td align="left">1.695 (0.654&#8211;4.386)</td><td align="left">0.274</td><td align="left">1.910 (0.697&#8211;5.229)</td><td align="left">0.208</td></tr>
###xml 2248 2252 2248 2252 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;A/A</td>
###xml 2252 2253 2252 2253 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2253 2260 2253 2260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1 (3.3)</td>
###xml 2260 2267 2260 2267 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (2.4)</td>
###xml 2267 2287 2267 2287 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.600 (0.138&#8211;18.519)</td>
###xml 2287 2292 2287 2292 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.568</td>
###xml 2292 2312 2292 2312 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.616 (0.115&#8211;22.779)</td>
###xml 2312 2317 2312 2317 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.722</td>
###xml 2248 2317 2248 2317 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;A/A</td><td char="." align="char">3</td><td align="left">1 (3.3)</td><td align="left">2 (2.4)</td><td align="left">1.600 (0.138&#8211;18.519)</td><td align="left">0.568</td><td align="left">1.616 (0.115&#8211;22.779)</td><td align="left">0.722</td></tr>
###xml 2317 2325 2317 2325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;G/A+A/A</td>
###xml 2325 2327 2325 2327 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29</td>
###xml 2327 2336 2327 2336 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (33.3)</td>
###xml 2336 2345 2336 2345 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">19 (22.9)</td>
###xml 2345 2364 2345 2364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.684 (0.674&#8211;4.202)</td>
###xml 2364 2369 2364 2369 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.262</td>
###xml 2369 2388 2369 2388 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.879 (0.710&#8211;4.968)</td>
###xml 2388 2393 2388 2393 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.204</td>
###xml 2317 2393 2317 2393 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;G/A+A/A</td><td char="." align="char">29</td><td align="left">10 (33.3)</td><td align="left">19 (22.9)</td><td align="left">1.684 (0.674&#8211;4.202)</td><td align="left">0.262</td><td align="left">1.879 (0.710&#8211;4.968)</td><td align="left">0.204</td></tr>
###xml 2393 2410 2393 2410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">MRP2 (Ile1324Ile)</td>
###xml 2393 2410 2393 2410 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">MRP2 (Ile1324Ile)</td></tr>
###xml 2410 2414 2410 2414 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/C</td>
###xml 2414 2416 2414 2416 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">74</td>
###xml 2416 2425 2416 2425 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">20 (66.7)</td>
###xml 2425 2434 2425 2434 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">54 (65.1)</td>
###xml 2434 2435 2434 2435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 2435 2435 2435 2435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2435 2435 2435 2435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2435 2435 2435 2435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2410 2435 2410 2435 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/C</td><td char="." align="char">74</td><td align="left">20 (66.7)</td><td align="left">54 (65.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 2435 2439 2435 2439 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/T</td>
###xml 2439 2441 2439 2441 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 2441 2449 2441 2449 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8 (26.7)</td>
###xml 2449 2458 2449 2458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25 (30.1)</td>
###xml 2458 2477 2458 2477 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.864 (0.335&#8211;2.227)</td>
###xml 2477 2482 2477 2482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.762</td>
###xml 2482 2501 2482 2501 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.066 (0.385&#8211;2.951)</td>
###xml 2501 2506 2501 2506 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.901</td>
###xml 2435 2506 2435 2506 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/T</td><td char="." align="char">33</td><td align="left">8 (26.7)</td><td align="left">25 (30.1)</td><td align="left">0.864 (0.335&#8211;2.227)</td><td align="left">0.762</td><td align="left">1.066 (0.385&#8211;2.951)</td><td align="left">0.901</td></tr>
###xml 2506 2510 2506 2510 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;T/T</td>
###xml 2510 2511 2510 2511 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2511 2518 2511 2518 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (6.7)</td>
###xml 2518 2525 2518 2525 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (4.8)</td>
###xml 2525 2544 2525 2544 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.350 (0.229&#8211;7.937)</td>
###xml 2544 2549 2544 2549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.665</td>
###xml 2549 2569 2549 2569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.508 (0.210&#8211;10.830)</td>
###xml 2569 2574 2569 2574 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.683</td>
###xml 2506 2574 2506 2574 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;T/T</td><td char="." align="char">6</td><td align="left">2 (6.7)</td><td align="left">4 (4.8)</td><td align="left">1.350 (0.229&#8211;7.937)</td><td align="left">0.665</td><td align="left">1.508 (0.210&#8211;10.830)</td><td align="left">0.683</td></tr>
###xml 2574 2582 2574 2582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C/T+T/T</td>
###xml 2582 2584 2582 2584 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">39</td>
###xml 2584 2593 2584 2593 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (33.3)</td>
###xml 2593 2602 2593 2602 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">29 (34.9)</td>
###xml 2602 2621 2602 2621 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.931 (0.385&#8211;2.252)</td>
###xml 2621 2626 2621 2626 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.874</td>
###xml 2626 2645 2626 2645 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.133 (0.441&#8211;2.911)</td>
###xml 2645 2650 2645 2650 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.796</td>
###xml 2574 2650 2574 2650 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C/T+T/T</td><td char="." align="char">39</td><td align="left">10 (33.3)</td><td align="left">29 (34.9)</td><td align="left">0.931 (0.385&#8211;2.252)</td><td align="left">0.874</td><td align="left">1.133 (0.441&#8211;2.911)</td><td align="left">0.796</td></tr>
###xml 2650 2667 2650 2667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">GSTP1 (Ile105Val)</td>
###xml 2650 2667 2650 2667 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">GSTP1 (Ile105Val)</td></tr>
###xml 2667 2671 2667 2671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;A/A</td>
###xml 2671 2673 2671 2673 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71</td>
###xml 2673 2682 2673 2682 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13 (43.3)</td>
###xml 2682 2691 2682 2691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">58 (69.9)</td>
###xml 2691 2692 2691 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 2692 2692 2692 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2692 2692 2692 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2692 2692 2692 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2667 2692 2667 2692 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;A/A</td><td char="." align="char">71</td><td align="left">13 (43.3)</td><td align="left">58 (69.9)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 2692 2696 2692 2696 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;A/G</td>
###xml 2696 2698 2696 2698 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 2698 2707 2698 2707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (50.0)</td>
###xml 2707 2716 2707 2716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">23 (27.7)</td>
###xml 2716 2735 2716 2735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.907 (1.200&#8211;7.042)</td>
###xml 2735 2740 2735 2740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.016</td>
###xml 2740 2759 2740 2759 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.788 (1.106&#8211;7.029)</td>
###xml 2759 2764 2759 2764 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.030</td>
###xml 2692 2764 2692 2764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;A/G</td><td char="." align="char">38</td><td align="left">15 (50.0)</td><td align="left">23 (27.7)</td><td align="left">2.907 (1.200&#8211;7.042)</td><td align="left">0.016</td><td align="left">2.788 (1.106&#8211;7.029)</td><td align="left">0.030</td></tr>
###xml 2764 2768 2764 2768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;G/G</td>
###xml 2768 2769 2768 2769 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2769 2776 2769 2776 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (6.7)</td>
###xml 2776 2783 2776 2783 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (2.4)</td>
###xml 2783 2803 2783 2803 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.464 (0.574&#8211;34.483)</td>
###xml 2803 2808 2803 2808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.176</td>
###xml 2808 2828 2808 2828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.083 (0.457&#8211;36.463)</td>
###xml 2828 2833 2828 2833 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.208</td>
###xml 2764 2833 2764 2833 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;G/G</td><td char="." align="char">4</td><td align="left">2 (6.7)</td><td align="left">2 (2.4)</td><td align="left">4.464 (0.574&#8211;34.483)</td><td align="left">0.176</td><td align="left">4.083 (0.457&#8211;36.463)</td><td align="left">0.208</td></tr>
###xml 2833 2841 2833 2841 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;A/G+G/G</td>
###xml 2841 2843 2841 2843 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 2843 2852 2843 2852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17 (56.7)</td>
###xml 2852 2861 2852 2861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25 (30.1)</td>
###xml 2861 2880 2861 2880 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.030 (1.282&#8211;7.194)</td>
###xml 2880 2885 2880 2885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.010</td>
###xml 2885 2904 2885 2904 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.881 (1.167&#8211;7.113)</td>
###xml 2904 2909 2904 2909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.022</td>
###xml 2833 2909 2833 2909 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;A/G+G/G</td><td char="." align="char">42</td><td align="left">17 (56.7)</td><td align="left">25 (30.1)</td><td align="left">3.030 (1.282&#8211;7.194)</td><td align="left">0.010</td><td align="left">2.881 (1.167&#8211;7.113)</td><td align="left">0.022</td></tr>
###xml 1875 2909 1875 2909 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="8">MRP2 (C-24T)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">66</td><td align="left">11 (36.7)</td><td align="left">55 (66.3)</td><td align="left">1</td><td align="left">0.015</td><td align="left">4.069 (1.518&#8211;10.910)</td><td align="left">0.005</td></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">43</td><td align="left">16 (53.3)</td><td align="left">27 (32.5)</td><td align="left">2.959 (1.211&#8211;7.246)</td><td align="left">0.023</td><td align="left">10.514 (0.842&#8211;131.319)</td><td align="left">0.068</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">4</td><td align="left">3 (10.0)</td><td align="left">1 (1.2)</td><td align="left">14.925 (1.425&#8211;166.667)</td><td align="left">0.005</td><td align="left">4.493 (1.728&#8211;11.682)</td><td align="left">0.002</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">47</td><td align="left">19 (63.3)</td><td align="left">28 (33.7)</td><td align="left">3.390 (1.420&#8211;8.130)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">MRP2 (Val417Ile)</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">84</td><td align="left">20 (66.7)</td><td align="left">64 (77.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;G/A</td><td char="." align="char">26</td><td align="left">9 (30.0)</td><td align="left">17 (20.5)</td><td align="left">1.695 (0.654&#8211;4.386)</td><td align="left">0.274</td><td align="left">1.910 (0.697&#8211;5.229)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">3</td><td align="left">1 (3.3)</td><td align="left">2 (2.4)</td><td align="left">1.600 (0.138&#8211;18.519)</td><td align="left">0.568</td><td align="left">1.616 (0.115&#8211;22.779)</td><td align="left">0.722</td></tr><tr><td align="left">&#160;G/A+A/A</td><td char="." align="char">29</td><td align="left">10 (33.3)</td><td align="left">19 (22.9)</td><td align="left">1.684 (0.674&#8211;4.202)</td><td align="left">0.262</td><td align="left">1.879 (0.710&#8211;4.968)</td><td align="left">0.204</td></tr><tr><td align="left" colspan="8">MRP2 (Ile1324Ile)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">74</td><td align="left">20 (66.7)</td><td align="left">54 (65.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">33</td><td align="left">8 (26.7)</td><td align="left">25 (30.1)</td><td align="left">0.864 (0.335&#8211;2.227)</td><td align="left">0.762</td><td align="left">1.066 (0.385&#8211;2.951)</td><td align="left">0.901</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">6</td><td align="left">2 (6.7)</td><td align="left">4 (4.8)</td><td align="left">1.350 (0.229&#8211;7.937)</td><td align="left">0.665</td><td align="left">1.508 (0.210&#8211;10.830)</td><td align="left">0.683</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">39</td><td align="left">10 (33.3)</td><td align="left">29 (34.9)</td><td align="left">0.931 (0.385&#8211;2.252)</td><td align="left">0.874</td><td align="left">1.133 (0.441&#8211;2.911)</td><td align="left">0.796</td></tr><tr><td align="left" colspan="8">GSTP1 (Ile105Val)</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">71</td><td align="left">13 (43.3)</td><td align="left">58 (69.9)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;A/G</td><td char="." align="char">38</td><td align="left">15 (50.0)</td><td align="left">23 (27.7)</td><td align="left">2.907 (1.200&#8211;7.042)</td><td align="left">0.016</td><td align="left">2.788 (1.106&#8211;7.029)</td><td align="left">0.030</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">4</td><td align="left">2 (6.7)</td><td align="left">2 (2.4)</td><td align="left">4.464 (0.574&#8211;34.483)</td><td align="left">0.176</td><td align="left">4.083 (0.457&#8211;36.463)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/G+G/G</td><td char="." align="char">42</td><td align="left">17 (56.7)</td><td align="left">25 (30.1)</td><td align="left">3.030 (1.282&#8211;7.194)</td><td align="left">0.010</td><td align="left">2.881 (1.167&#8211;7.113)</td><td align="left">0.022</td></tr></tbody>
###xml 1748 2909 1748 2909 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Genotype</th><th align="left" rowspan="2">Cases</th><th align="left" colspan="2">Response to chemotherapy</th><th align="left" rowspan="2">OR (95% CI)</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Adjusted OR (95% CI)</th><th align="left" rowspan="2">Adjusted <italic>P</italic> value</th></tr><tr><th align="left">CR&#160;+&#160;PR (%) <italic>n</italic>&#160;=&#160;30</th><th align="left">SD&#160;+&#160;PD (%) <italic>n</italic>&#160;=&#160;83</th></tr></thead><tbody><tr><td align="left" colspan="8">MRP2 (C-24T)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">66</td><td align="left">11 (36.7)</td><td align="left">55 (66.3)</td><td align="left">1</td><td align="left">0.015</td><td align="left">4.069 (1.518&#8211;10.910)</td><td align="left">0.005</td></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">43</td><td align="left">16 (53.3)</td><td align="left">27 (32.5)</td><td align="left">2.959 (1.211&#8211;7.246)</td><td align="left">0.023</td><td align="left">10.514 (0.842&#8211;131.319)</td><td align="left">0.068</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">4</td><td align="left">3 (10.0)</td><td align="left">1 (1.2)</td><td align="left">14.925 (1.425&#8211;166.667)</td><td align="left">0.005</td><td align="left">4.493 (1.728&#8211;11.682)</td><td align="left">0.002</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">47</td><td align="left">19 (63.3)</td><td align="left">28 (33.7)</td><td align="left">3.390 (1.420&#8211;8.130)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">MRP2 (Val417Ile)</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">84</td><td align="left">20 (66.7)</td><td align="left">64 (77.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;G/A</td><td char="." align="char">26</td><td align="left">9 (30.0)</td><td align="left">17 (20.5)</td><td align="left">1.695 (0.654&#8211;4.386)</td><td align="left">0.274</td><td align="left">1.910 (0.697&#8211;5.229)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">3</td><td align="left">1 (3.3)</td><td align="left">2 (2.4)</td><td align="left">1.600 (0.138&#8211;18.519)</td><td align="left">0.568</td><td align="left">1.616 (0.115&#8211;22.779)</td><td align="left">0.722</td></tr><tr><td align="left">&#160;G/A+A/A</td><td char="." align="char">29</td><td align="left">10 (33.3)</td><td align="left">19 (22.9)</td><td align="left">1.684 (0.674&#8211;4.202)</td><td align="left">0.262</td><td align="left">1.879 (0.710&#8211;4.968)</td><td align="left">0.204</td></tr><tr><td align="left" colspan="8">MRP2 (Ile1324Ile)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">74</td><td align="left">20 (66.7)</td><td align="left">54 (65.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">33</td><td align="left">8 (26.7)</td><td align="left">25 (30.1)</td><td align="left">0.864 (0.335&#8211;2.227)</td><td align="left">0.762</td><td align="left">1.066 (0.385&#8211;2.951)</td><td align="left">0.901</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">6</td><td align="left">2 (6.7)</td><td align="left">4 (4.8)</td><td align="left">1.350 (0.229&#8211;7.937)</td><td align="left">0.665</td><td align="left">1.508 (0.210&#8211;10.830)</td><td align="left">0.683</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">39</td><td align="left">10 (33.3)</td><td align="left">29 (34.9)</td><td align="left">0.931 (0.385&#8211;2.252)</td><td align="left">0.874</td><td align="left">1.133 (0.441&#8211;2.911)</td><td align="left">0.796</td></tr><tr><td align="left" colspan="8">GSTP1 (Ile105Val)</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">71</td><td align="left">13 (43.3)</td><td align="left">58 (69.9)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;A/G</td><td char="." align="char">38</td><td align="left">15 (50.0)</td><td align="left">23 (27.7)</td><td align="left">2.907 (1.200&#8211;7.042)</td><td align="left">0.016</td><td align="left">2.788 (1.106&#8211;7.029)</td><td align="left">0.030</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">4</td><td align="left">2 (6.7)</td><td align="left">2 (2.4)</td><td align="left">4.464 (0.574&#8211;34.483)</td><td align="left">0.176</td><td align="left">4.083 (0.457&#8211;36.463)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/G+G/G</td><td char="." align="char">42</td><td align="left">17 (56.7)</td><td align="left">25 (30.1)</td><td align="left">3.030 (1.282&#8211;7.194)</td><td align="left">0.010</td><td align="left">2.881 (1.167&#8211;7.113)</td><td align="left">0.022</td></tr></tbody></table>
###xml 2909 3054 2909 3054 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens</p>
###xml 2909 3054 2909 3054 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens</p></table-wrap-foot>
###xml 1673 3054 1673 3054 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="42">Genotype and response to chemotherapy among NSCLC patients (<italic>n</italic>&#160;=&#160;113)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Genotype</th><th align="left" rowspan="2">Cases</th><th align="left" colspan="2">Response to chemotherapy</th><th align="left" rowspan="2">OR (95% CI)</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Adjusted OR (95% CI)</th><th align="left" rowspan="2">Adjusted <italic>P</italic> value</th></tr><tr><th align="left">CR&#160;+&#160;PR (%) <italic>n</italic>&#160;=&#160;30</th><th align="left">SD&#160;+&#160;PD (%) <italic>n</italic>&#160;=&#160;83</th></tr></thead><tbody><tr><td align="left" colspan="8">MRP2 (C-24T)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">66</td><td align="left">11 (36.7)</td><td align="left">55 (66.3)</td><td align="left">1</td><td align="left">0.015</td><td align="left">4.069 (1.518&#8211;10.910)</td><td align="left">0.005</td></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">43</td><td align="left">16 (53.3)</td><td align="left">27 (32.5)</td><td align="left">2.959 (1.211&#8211;7.246)</td><td align="left">0.023</td><td align="left">10.514 (0.842&#8211;131.319)</td><td align="left">0.068</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">4</td><td align="left">3 (10.0)</td><td align="left">1 (1.2)</td><td align="left">14.925 (1.425&#8211;166.667)</td><td align="left">0.005</td><td align="left">4.493 (1.728&#8211;11.682)</td><td align="left">0.002</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">47</td><td align="left">19 (63.3)</td><td align="left">28 (33.7)</td><td align="left">3.390 (1.420&#8211;8.130)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">MRP2 (Val417Ile)</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">84</td><td align="left">20 (66.7)</td><td align="left">64 (77.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;G/A</td><td char="." align="char">26</td><td align="left">9 (30.0)</td><td align="left">17 (20.5)</td><td align="left">1.695 (0.654&#8211;4.386)</td><td align="left">0.274</td><td align="left">1.910 (0.697&#8211;5.229)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">3</td><td align="left">1 (3.3)</td><td align="left">2 (2.4)</td><td align="left">1.600 (0.138&#8211;18.519)</td><td align="left">0.568</td><td align="left">1.616 (0.115&#8211;22.779)</td><td align="left">0.722</td></tr><tr><td align="left">&#160;G/A+A/A</td><td char="." align="char">29</td><td align="left">10 (33.3)</td><td align="left">19 (22.9)</td><td align="left">1.684 (0.674&#8211;4.202)</td><td align="left">0.262</td><td align="left">1.879 (0.710&#8211;4.968)</td><td align="left">0.204</td></tr><tr><td align="left" colspan="8">MRP2 (Ile1324Ile)</td></tr><tr><td align="left">&#160;C/C</td><td char="." align="char">74</td><td align="left">20 (66.7)</td><td align="left">54 (65.1)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;C/T</td><td char="." align="char">33</td><td align="left">8 (26.7)</td><td align="left">25 (30.1)</td><td align="left">0.864 (0.335&#8211;2.227)</td><td align="left">0.762</td><td align="left">1.066 (0.385&#8211;2.951)</td><td align="left">0.901</td></tr><tr><td align="left">&#160;T/T</td><td char="." align="char">6</td><td align="left">2 (6.7)</td><td align="left">4 (4.8)</td><td align="left">1.350 (0.229&#8211;7.937)</td><td align="left">0.665</td><td align="left">1.508 (0.210&#8211;10.830)</td><td align="left">0.683</td></tr><tr><td align="left">&#160;C/T+T/T</td><td char="." align="char">39</td><td align="left">10 (33.3)</td><td align="left">29 (34.9)</td><td align="left">0.931 (0.385&#8211;2.252)</td><td align="left">0.874</td><td align="left">1.133 (0.441&#8211;2.911)</td><td align="left">0.796</td></tr><tr><td align="left" colspan="8">GSTP1 (Ile105Val)</td></tr><tr><td align="left">&#160;A/A</td><td char="." align="char">71</td><td align="left">13 (43.3)</td><td align="left">58 (69.9)</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;A/G</td><td char="." align="char">38</td><td align="left">15 (50.0)</td><td align="left">23 (27.7)</td><td align="left">2.907 (1.200&#8211;7.042)</td><td align="left">0.016</td><td align="left">2.788 (1.106&#8211;7.029)</td><td align="left">0.030</td></tr><tr><td align="left">&#160;G/G</td><td char="." align="char">4</td><td align="left">2 (6.7)</td><td align="left">2 (2.4)</td><td align="left">4.464 (0.574&#8211;34.483)</td><td align="left">0.176</td><td align="left">4.083 (0.457&#8211;36.463)</td><td align="left">0.208</td></tr><tr><td align="left">&#160;A/G+G/G</td><td char="." align="char">42</td><td align="left">17 (56.7)</td><td align="left">25 (30.1)</td><td align="left">3.030 (1.282&#8211;7.194)</td><td align="left">0.010</td><td align="left">2.881 (1.167&#8211;7.113)</td><td align="left">0.022</td></tr></tbody></table><table-wrap-foot><p textid="43">Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens</p></table-wrap-foot></table-wrap>
###xml 3054 3061 3054 3061 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 3061 3079 3061 3079 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Allele frequencies</p>
###xml 3061 3079 3061 3079 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Allele frequencies</p></caption>
###xml 3079 3084 3079 3084 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus</th>
###xml 3084 3090 3084 3090 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Allele</th>
###xml 3090 3099 3090 3099 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Frequency</th>
###xml 3099 3113 3099 3113 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Standard Error</th>
###xml 3113 3119 3113 3119 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 3079 3119 3079 3119 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Locus</th><th align="left">Allele</th><th align="left">Frequency</th><th align="left">Standard Error</th><th align="left">95% CI</th></tr>
###xml 3079 3119 3079 3119 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Locus</th><th align="left">Allele</th><th align="left">Frequency</th><th align="left">Standard Error</th><th align="left">95% CI</th></tr></thead>
###xml 3119 3131 3119 3131 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">MRP2 (C-24T)</td>
###xml 3131 3132 3131 3132 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C</td>
###xml 3132 3138 3132 3138 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.7743</td>
###xml 3138 3144 3138 3144 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0265</td>
###xml 3144 3157 3144 3157 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.7168&#8211;0.8230</td>
###xml 3119 3157 3119 3157 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">MRP2 (C-24T)</td><td align="left">C</td><td char="." align="char">0.7743</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.7168&#8211;0.8230</td></tr>
###xml 3157 3158 3157 3158 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T</td>
###xml 3158 3164 3158 3164 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2257</td>
###xml 3164 3170 3164 3170 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0265</td>
###xml 3170 3183 3170 3183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.1770&#8211;0.2832</td>
###xml 3157 3183 3157 3183 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T</td><td char="." align="char">0.2257</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.1770&#8211;0.2832</td></tr>
###xml 3183 3199 3183 3199 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">MRP2 (Val417Ile)</td>
###xml 3199 3200 3199 3200 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A</td>
###xml 3200 3206 3200 3206 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1416</td>
###xml 3206 3212 3206 3212 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0238</td>
###xml 3212 3225 3212 3225 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.0973&#8211;0.1903</td>
###xml 3183 3225 3183 3225 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">MRP2 (Val417Ile)</td><td align="left">A</td><td char="." align="char">0.1416</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.0973&#8211;0.1903</td></tr>
###xml 3225 3226 3225 3226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G</td>
###xml 3226 3232 3226 3232 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8584</td>
###xml 3232 3238 3232 3238 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0238</td>
###xml 3238 3251 3238 3251 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.8097&#8211;0.9027</td>
###xml 3225 3251 3225 3251 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">G</td><td char="." align="char">0.8584</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.8097&#8211;0.9027</td></tr>
###xml 3251 3268 3251 3268 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">MRP2 (Ile1324Ile)</td>
###xml 3268 3269 3268 3269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C</td>
###xml 3269 3275 3269 3275 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8009</td>
###xml 3275 3281 3275 3281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0277</td>
###xml 3281 3294 3281 3294 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.7434&#8211;0.8540</td>
###xml 3251 3294 3251 3294 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">MRP2 (Ile1324Ile)</td><td align="left">C</td><td char="." align="char">0.8009</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.7434&#8211;0.8540</td></tr>
###xml 3294 3295 3294 3295 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T</td>
###xml 3295 3301 3295 3301 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1991</td>
###xml 3301 3307 3301 3307 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0277</td>
###xml 3307 3320 3307 3320 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.1460&#8211;0.2566</td>
###xml 3294 3320 3294 3320 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T</td><td char="." align="char">0.1991</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.1460&#8211;0.2566</td></tr>
###xml 3320 3337 3320 3337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">GSTP1 (Ile105Val)</td>
###xml 3337 3338 3337 3338 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A</td>
###xml 3338 3344 3338 3344 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.7965</td>
###xml 3344 3350 3344 3350 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0263</td>
###xml 3350 3363 3350 3363 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.7434&#8211;0.8451</td>
###xml 3320 3363 3320 3363 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">GSTP1 (Ile105Val)</td><td align="left">A</td><td char="." align="char">0.7965</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.7434&#8211;0.8451</td></tr>
###xml 3363 3364 3363 3364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G</td>
###xml 3364 3370 3364 3370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2035</td>
###xml 3370 3376 3370 3376 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0263</td>
###xml 3376 3389 3376 3389 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.1549&#8211;0.2566</td>
###xml 3363 3389 3363 3389 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">G</td><td char="." align="char">0.2035</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.1549&#8211;0.2566</td></tr>
###xml 3119 3389 3119 3389 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="2">MRP2 (C-24T)</td><td align="left">C</td><td char="." align="char">0.7743</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.7168&#8211;0.8230</td></tr><tr><td align="left">T</td><td char="." align="char">0.2257</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.1770&#8211;0.2832</td></tr><tr><td align="left" rowspan="2">MRP2 (Val417Ile)</td><td align="left">A</td><td char="." align="char">0.1416</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.0973&#8211;0.1903</td></tr><tr><td align="left">G</td><td char="." align="char">0.8584</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.8097&#8211;0.9027</td></tr><tr><td align="left" rowspan="2">MRP2 (Ile1324Ile)</td><td align="left">C</td><td char="." align="char">0.8009</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.7434&#8211;0.8540</td></tr><tr><td align="left">T</td><td char="." align="char">0.1991</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.1460&#8211;0.2566</td></tr><tr><td align="left" rowspan="2">GSTP1 (Ile105Val)</td><td align="left">A</td><td char="." align="char">0.7965</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.7434&#8211;0.8451</td></tr><tr><td align="left">G</td><td char="." align="char">0.2035</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.1549&#8211;0.2566</td></tr></tbody>
###xml 3079 3389 3079 3389 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Allele</th><th align="left">Frequency</th><th align="left">Standard Error</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="2">MRP2 (C-24T)</td><td align="left">C</td><td char="." align="char">0.7743</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.7168&#8211;0.8230</td></tr><tr><td align="left">T</td><td char="." align="char">0.2257</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.1770&#8211;0.2832</td></tr><tr><td align="left" rowspan="2">MRP2 (Val417Ile)</td><td align="left">A</td><td char="." align="char">0.1416</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.0973&#8211;0.1903</td></tr><tr><td align="left">G</td><td char="." align="char">0.8584</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.8097&#8211;0.9027</td></tr><tr><td align="left" rowspan="2">MRP2 (Ile1324Ile)</td><td align="left">C</td><td char="." align="char">0.8009</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.7434&#8211;0.8540</td></tr><tr><td align="left">T</td><td char="." align="char">0.1991</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.1460&#8211;0.2566</td></tr><tr><td align="left" rowspan="2">GSTP1 (Ile105Val)</td><td align="left">A</td><td char="." align="char">0.7965</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.7434&#8211;0.8451</td></tr><tr><td align="left">G</td><td char="." align="char">0.2035</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.1549&#8211;0.2566</td></tr></tbody></table>
###xml 3054 3389 3054 3389 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="44">Allele frequencies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Allele</th><th align="left">Frequency</th><th align="left">Standard Error</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="2">MRP2 (C-24T)</td><td align="left">C</td><td char="." align="char">0.7743</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.7168&#8211;0.8230</td></tr><tr><td align="left">T</td><td char="." align="char">0.2257</td><td char="." align="char">0.0265</td><td char="&#8211;" align="char">0.1770&#8211;0.2832</td></tr><tr><td align="left" rowspan="2">MRP2 (Val417Ile)</td><td align="left">A</td><td char="." align="char">0.1416</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.0973&#8211;0.1903</td></tr><tr><td align="left">G</td><td char="." align="char">0.8584</td><td char="." align="char">0.0238</td><td char="&#8211;" align="char">0.8097&#8211;0.9027</td></tr><tr><td align="left" rowspan="2">MRP2 (Ile1324Ile)</td><td align="left">C</td><td char="." align="char">0.8009</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.7434&#8211;0.8540</td></tr><tr><td align="left">T</td><td char="." align="char">0.1991</td><td char="." align="char">0.0277</td><td char="&#8211;" align="char">0.1460&#8211;0.2566</td></tr><tr><td align="left" rowspan="2">GSTP1 (Ile105Val)</td><td align="left">A</td><td char="." align="char">0.7965</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.7434&#8211;0.8451</td></tr><tr><td align="left">G</td><td char="." align="char">0.2035</td><td char="." align="char">0.0263</td><td char="&#8211;" align="char">0.1549&#8211;0.2566</td></tr></tbody></table></table-wrap>
###xml 3389 3396 3389 3396 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;5</label>
###xml 3396 3416 3396 3416 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Genotype frequencies</p>
###xml 3396 3416 3396 3416 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Genotype frequencies</p></caption>
###xml 3416 3421 3416 3421 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus</th>
###xml 3421 3429 3421 3429 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Genotype</th>
###xml 3429 3438 3429 3438 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Frequency</th>
###xml 3438 3447 3438 3447 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HWD coeff</th>
###xml 3447 3461 3447 3461 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Standard error</th>
###xml 3461 3467 3461 3467 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">95% CI</th>
###xml 3416 3467 3416 3467 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Locus</th><th align="left">Genotype</th><th align="left">Frequency</th><th align="left">HWD coeff</th><th align="left">Standard error</th><th align="left">95% CI</th></tr>
###xml 3416 3467 3416 3467 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Locus</th><th align="left">Genotype</th><th align="left">Frequency</th><th align="left">HWD coeff</th><th align="left">Standard error</th><th align="left">95% CI</th></tr></thead>
###xml 3467 3479 3467 3479 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">MRP2 (C-24T)</td>
###xml 3479 3482 3479 3482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C/C</td>
###xml 3482 3488 3482 3488 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.5841</td>
###xml 3488 3495 3488 3495 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0155</td>
###xml 3495 3501 3495 3501 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0151</td>
###xml 3501 3515 3501 3515 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0459&#8211;0.0149</td>
###xml 3467 3515 3467 3515 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">MRP2 (C-24T)</td><td align="left">C/C</td><td char="." align="char">0.5841</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr>
###xml 3515 3518 3515 3518 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C/T</td>
###xml 3518 3524 3518 3524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.3805</td>
###xml 3524 3531 3524 3531 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0155</td>
###xml 3531 3537 3531 3537 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0151</td>
###xml 3537 3551 3537 3551 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0459&#8211;0.0149</td>
###xml 3515 3551 3515 3551 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C/T</td><td char="." align="char">0.3805</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr>
###xml 3551 3554 3551 3554 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T/T</td>
###xml 3554 3560 3554 3560 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0354</td>
###xml 3560 3567 3560 3567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0155</td>
###xml 3567 3573 3567 3573 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0151</td>
###xml 3573 3587 3573 3587 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0459&#8211;0.0149</td>
###xml 3551 3587 3551 3587 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T/T</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr>
###xml 3587 3603 3587 3603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">MRP2 (Val417Ile)</td>
###xml 3603 3606 3603 3606 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A/A</td>
###xml 3606 3612 3606 3612 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0265</td>
###xml 3612 3618 3612 3618 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0065</td>
###xml 3618 3624 3618 3624 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0126</td>
###xml 3624 3638 3624 3638 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0165&#8211;0.0318</td>
###xml 3587 3638 3587 3638 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">MRP2 (Val417Ile)</td><td align="left">A/A</td><td char="." align="char">0.0265</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr>
###xml 3638 3641 3638 3641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A/G</td>
###xml 3641 3647 3641 3647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2301</td>
###xml 3647 3653 3647 3653 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0065</td>
###xml 3653 3659 3653 3659 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0126</td>
###xml 3659 3673 3659 3673 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0165&#8211;0.0318</td>
###xml 3638 3673 3638 3673 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">A/G</td><td char="." align="char">0.2301</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr>
###xml 3673 3676 3673 3676 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G/G</td>
###xml 3676 3682 3676 3682 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.7434</td>
###xml 3682 3688 3682 3688 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0065</td>
###xml 3688 3694 3688 3694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0126</td>
###xml 3694 3708 3694 3708 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0165&#8211;0.0318</td>
###xml 3673 3708 3673 3708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">G/G</td><td char="." align="char">0.7434</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr>
###xml 3708 3725 3708 3725 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">MRP2 (Ile1324Ile)</td>
###xml 3725 3728 3725 3728 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C/C</td>
###xml 3728 3734 3728 3734 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.6549</td>
###xml 3734 3740 3734 3740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0135</td>
###xml 3740 3746 3740 3746 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0163</td>
###xml 3746 3760 3746 3760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0185&#8211;0.0484</td>
###xml 3708 3760 3708 3760 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">MRP2 (Ile1324Ile)</td><td align="left">C/C</td><td char="." align="char">0.6549</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr>
###xml 3760 3763 3760 3763 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C/T</td>
###xml 3763 3769 3763 3769 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2920</td>
###xml 3769 3775 3769 3775 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0135</td>
###xml 3775 3781 3775 3781 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0163</td>
###xml 3781 3795 3781 3795 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0185&#8211;0.0484</td>
###xml 3760 3795 3760 3795 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C/T</td><td char="." align="char">0.2920</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr>
###xml 3795 3798 3795 3798 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T/T</td>
###xml 3798 3804 3798 3804 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0531</td>
###xml 3804 3810 3804 3810 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0135</td>
###xml 3810 3816 3810 3816 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0163</td>
###xml 3816 3830 3816 3830 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0185&#8211;0.0484</td>
###xml 3795 3830 3795 3830 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T/T</td><td char="." align="char">0.0531</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr>
###xml 3830 3847 3830 3847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">GSTP1 (Ile105Val)</td>
###xml 3847 3850 3847 3850 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A/A</td>
###xml 3850 3856 3850 3856 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.6283</td>
###xml 3856 3863 3856 3863 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0060</td>
###xml 3863 3869 3863 3869 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0146</td>
###xml 3869 3883 3869 3883 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0313&#8211;0.0218</td>
###xml 3830 3883 3830 3883 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">GSTP1 (Ile105Val)</td><td align="left">A/A</td><td char="." align="char">0.6283</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr>
###xml 3883 3886 3883 3886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A/G</td>
###xml 3886 3892 3886 3892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.3363</td>
###xml 3892 3899 3892 3899 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0060</td>
###xml 3899 3905 3899 3905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0146</td>
###xml 3905 3919 3905 3919 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0313&#8211;0.0218</td>
###xml 3883 3919 3883 3919 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">A/G</td><td char="." align="char">0.3363</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr>
###xml 3919 3922 3919 3922 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G/G</td>
###xml 3922 3928 3922 3928 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0354</td>
###xml 3928 3935 3928 3935 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0060</td>
###xml 3935 3941 3935 3941 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0146</td>
###xml 3941 3955 3941 3955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.0313&#8211;0.0218</td>
###xml 3919 3955 3919 3955 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">G/G</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr>
###xml 3467 3955 3467 3955 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="3">MRP2 (C-24T)</td><td align="left">C/C</td><td char="." align="char">0.5841</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.3805</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left" rowspan="3">MRP2 (Val417Ile)</td><td align="left">A/A</td><td char="." align="char">0.0265</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.2301</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.7434</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left" rowspan="3">MRP2 (Ile1324Ile)</td><td align="left">C/C</td><td char="." align="char">0.6549</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.2920</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0531</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left" rowspan="3">GSTP1 (Ile105Val)</td><td align="left">A/A</td><td char="." align="char">0.6283</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.3363</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr></tbody>
###xml 3416 3955 3416 3955 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Genotype</th><th align="left">Frequency</th><th align="left">HWD coeff</th><th align="left">Standard error</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="3">MRP2 (C-24T)</td><td align="left">C/C</td><td char="." align="char">0.5841</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.3805</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left" rowspan="3">MRP2 (Val417Ile)</td><td align="left">A/A</td><td char="." align="char">0.0265</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.2301</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.7434</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left" rowspan="3">MRP2 (Ile1324Ile)</td><td align="left">C/C</td><td char="." align="char">0.6549</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.2920</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0531</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left" rowspan="3">GSTP1 (Ile105Val)</td><td align="left">A/A</td><td char="." align="char">0.6283</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.3363</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr></tbody></table>
###xml 3389 3955 3389 3955 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table&#160;5</label><caption><p textid="45">Genotype frequencies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left">Genotype</th><th align="left">Frequency</th><th align="left">HWD coeff</th><th align="left">Standard error</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="3">MRP2 (C-24T)</td><td align="left">C/C</td><td char="." align="char">0.5841</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.3805</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0155</td><td char="." align="char">0.0151</td><td char="." align="char">&#8722;0.0459&#8211;0.0149</td></tr><tr><td align="left" rowspan="3">MRP2 (Val417Ile)</td><td align="left">A/A</td><td char="." align="char">0.0265</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.2301</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.7434</td><td char="." align="char">0.0065</td><td char="." align="char">0.0126</td><td char="." align="char">&#8722;0.0165&#8211;0.0318</td></tr><tr><td align="left" rowspan="3">MRP2 (Ile1324Ile)</td><td align="left">C/C</td><td char="." align="char">0.6549</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">C/T</td><td char="." align="char">0.2920</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left">T/T</td><td char="." align="char">0.0531</td><td char="." align="char">0.0135</td><td char="." align="char">0.0163</td><td char="." align="char">&#8722;0.0185&#8211;0.0484</td></tr><tr><td align="left" rowspan="3">GSTP1 (Ile105Val)</td><td align="left">A/A</td><td char="." align="char">0.6283</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">A/G</td><td char="." align="char">0.3363</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr><tr><td align="left">G/G</td><td char="." align="char">0.0354</td><td char="." align="char">&#8722;0.0060</td><td char="." align="char">0.0146</td><td char="." align="char">&#8722;0.0313&#8211;0.0218</td></tr></tbody></table></table-wrap>
###xml 3955 3962 3955 3962 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;6</label>
###xml 3962 4042 3962 4042 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)</p>
###xml 3962 4042 3962 4042 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)</p></caption>
###xml 4042 4051 4042 4051 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Haplotype</th>
###xml 4051 4062 4051 4062 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Frequencies</th>
###xml 4062 4068 4062 4068 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">95% CI</th>
###xml 4068 4078 4068 4078 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Chi-square</th>
###xml 4078 4079 4078 4079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4078 4085 4078 4085 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>P</italic> value</th>
###xml 4085 4095 4085 4095 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Prob Exact</th>
###xml 4042 4095 4042 4095 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Haplotype</th><th align="left" colspan="3">Frequencies</th><th align="left" rowspan="2">95% CI</th><th align="left" rowspan="2">Chi-square</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Prob Exact</th></tr>
###xml 4095 4102 4095 4102 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Trait 1</th>
###xml 4102 4109 4102 4109 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Trait 2</th>
###xml 4109 4117 4109 4117 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Combined</th>
###xml 4095 4117 4095 4117 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Trait 1</th><th align="left">Trait 2</th><th align="left">Combined</th></tr>
###xml 4042 4117 4042 4117 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Haplotype</th><th align="left" colspan="3">Frequencies</th><th align="left" rowspan="2">95% CI</th><th align="left" rowspan="2">Chi-square</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Prob Exact</th></tr><tr><th align="left">Trait 1</th><th align="left">Trait 2</th><th align="left">Combined</th></tr></thead>
###xml 4117 4120 4117 4120 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C&#8211;A</td>
###xml 4120 4127 4120 4127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.71074</td>
###xml 4127 4134 4127 4134 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.43370</td>
###xml 4134 4141 4134 4141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.64446</td>
###xml 4141 4156 4141 4156 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.58192&#8211;0.70701</td>
###xml 4156 4163 4156 4163 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.8140</td>
###xml 4163 4169 4163 4169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 4169 4176 4169 4176 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 4117 4176 4117 4176 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C&#8211;A</td><td char="." align="char">0.71074</td><td char="." align="char">0.43370</td><td char="." align="char">0.64446</td><td char="&#8211;" align="char">0.58192&#8211;0.70701</td><td char="." align="char">14.8140</td><td char="." align="char">0.0001</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 4176 4179 4176 4179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C&#8211;G</td>
###xml 4179 4186 4179 4186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.11456</td>
###xml 4186 4193 4186 4193 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.19963</td>
###xml 4193 4200 4193 4200 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.12987</td>
###xml 4200 4215 4200 4215 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.08595&#8211;0.17380</td>
###xml 4215 4221 4215 4221 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9280</td>
###xml 4221 4227 4221 4227 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0871</td>
###xml 4227 4233 4227 4233 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1600</td>
###xml 4176 4233 4176 4233 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C&#8211;G</td><td char="." align="char">0.11456</td><td char="." align="char">0.19963</td><td char="." align="char">0.12987</td><td char="&#8211;" align="char">0.08595&#8211;0.17380</td><td char="." align="char">2.9280</td><td char="." align="char">0.0871</td><td char="." align="char">0.1600</td></tr>
###xml 4233 4236 4233 4236 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T&#8211;A</td>
###xml 4236 4243 4236 4243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.12661</td>
###xml 4243 4250 4243 4250 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.24963</td>
###xml 4250 4257 4250 4257 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.15200</td>
###xml 4257 4272 4257 4272 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.10509&#8211;0.19891</td>
###xml 4272 4278 4272 4278 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.2672</td>
###xml 4278 4284 4278 4284 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0217</td>
###xml 4284 4290 4284 4290 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0500</td>
###xml 4233 4290 4233 4290 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T&#8211;A</td><td char="." align="char">0.12661</td><td char="." align="char">0.24963</td><td char="." align="char">0.15200</td><td char="&#8211;" align="char">0.10509&#8211;0.19891</td><td char="." align="char">5.2672</td><td char="." align="char">0.0217</td><td char="." align="char">0.0500</td></tr>
###xml 4290 4293 4290 4293 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T&#8211;G</td>
###xml 4293 4300 4293 4300 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04809</td>
###xml 4300 4307 4300 4307 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.11703</td>
###xml 4307 4314 4307 4314 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.07367</td>
###xml 4314 4329 4314 4329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0.03953&#8211;0.10780</td>
###xml 4329 4335 4329 4335 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.2455</td>
###xml 4335 4341 4335 4341 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0716</td>
###xml 4341 4347 4341 4347 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1400</td>
###xml 4290 4347 4290 4347 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">T&#8211;G</td><td char="." align="char">0.04809</td><td char="." align="char">0.11703</td><td char="." align="char">0.07367</td><td char="&#8211;" align="char">0.03953&#8211;0.10780</td><td char="." align="char">3.2455</td><td char="." align="char">0.0716</td><td char="." align="char">0.1400</td></tr>
###xml 4117 4347 4117 4347 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">C&#8211;A</td><td char="." align="char">0.71074</td><td char="." align="char">0.43370</td><td char="." align="char">0.64446</td><td char="&#8211;" align="char">0.58192&#8211;0.70701</td><td char="." align="char">14.8140</td><td char="." align="char">0.0001</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">C&#8211;G</td><td char="." align="char">0.11456</td><td char="." align="char">0.19963</td><td char="." align="char">0.12987</td><td char="&#8211;" align="char">0.08595&#8211;0.17380</td><td char="." align="char">2.9280</td><td char="." align="char">0.0871</td><td char="." align="char">0.1600</td></tr><tr><td align="left">T&#8211;A</td><td char="." align="char">0.12661</td><td char="." align="char">0.24963</td><td char="." align="char">0.15200</td><td char="&#8211;" align="char">0.10509&#8211;0.19891</td><td char="." align="char">5.2672</td><td char="." align="char">0.0217</td><td char="." align="char">0.0500</td></tr><tr><td align="left">T&#8211;G</td><td char="." align="char">0.04809</td><td char="." align="char">0.11703</td><td char="." align="char">0.07367</td><td char="&#8211;" align="char">0.03953&#8211;0.10780</td><td char="." align="char">3.2455</td><td char="." align="char">0.0716</td><td char="." align="char">0.1400</td></tr></tbody>
###xml 4042 4347 4042 4347 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Haplotype</th><th align="left" colspan="3">Frequencies</th><th align="left" rowspan="2">95% CI</th><th align="left" rowspan="2">Chi-square</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Prob Exact</th></tr><tr><th align="left">Trait 1</th><th align="left">Trait 2</th><th align="left">Combined</th></tr></thead><tbody><tr><td align="left">C&#8211;A</td><td char="." align="char">0.71074</td><td char="." align="char">0.43370</td><td char="." align="char">0.64446</td><td char="&#8211;" align="char">0.58192&#8211;0.70701</td><td char="." align="char">14.8140</td><td char="." align="char">0.0001</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">C&#8211;G</td><td char="." align="char">0.11456</td><td char="." align="char">0.19963</td><td char="." align="char">0.12987</td><td char="&#8211;" align="char">0.08595&#8211;0.17380</td><td char="." align="char">2.9280</td><td char="." align="char">0.0871</td><td char="." align="char">0.1600</td></tr><tr><td align="left">T&#8211;A</td><td char="." align="char">0.12661</td><td char="." align="char">0.24963</td><td char="." align="char">0.15200</td><td char="&#8211;" align="char">0.10509&#8211;0.19891</td><td char="." align="char">5.2672</td><td char="." align="char">0.0217</td><td char="." align="char">0.0500</td></tr><tr><td align="left">T&#8211;G</td><td char="." align="char">0.04809</td><td char="." align="char">0.11703</td><td char="." align="char">0.07367</td><td char="&#8211;" align="char">0.03953&#8211;0.10780</td><td char="." align="char">3.2455</td><td char="." align="char">0.0716</td><td char="." align="char">0.1400</td></tr></tbody></table>
###xml 4347 4352 4347 4352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait</italic>
###xml 4379 4386 4379 4386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait 1</italic>
###xml 4393 4394 4393 4394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 4401 4408 4401 4408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait 2</italic>
###xml 4415 4416 4415 4416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 4347 4421 4347 4421 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><italic>Trait</italic> response to chemotherapy, <italic>Trait 1</italic> SD+PD <italic>n</italic>&#160;=&#160;83, <italic>Trait 2</italic> CR+PR <italic>n</italic>&#160;=&#160;30</p>
###xml 4347 4421 4347 4421 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47"><italic>Trait</italic> response to chemotherapy, <italic>Trait 1</italic> SD+PD <italic>n</italic>&#160;=&#160;83, <italic>Trait 2</italic> CR+PR <italic>n</italic>&#160;=&#160;30</p></table-wrap-foot>
###xml 3955 4421 3955 4421 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab6"><label>Table&#160;6</label><caption><p textid="46">Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Haplotype</th><th align="left" colspan="3">Frequencies</th><th align="left" rowspan="2">95% CI</th><th align="left" rowspan="2">Chi-square</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Prob Exact</th></tr><tr><th align="left">Trait 1</th><th align="left">Trait 2</th><th align="left">Combined</th></tr></thead><tbody><tr><td align="left">C&#8211;A</td><td char="." align="char">0.71074</td><td char="." align="char">0.43370</td><td char="." align="char">0.64446</td><td char="&#8211;" align="char">0.58192&#8211;0.70701</td><td char="." align="char">14.8140</td><td char="." align="char">0.0001</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">C&#8211;G</td><td char="." align="char">0.11456</td><td char="." align="char">0.19963</td><td char="." align="char">0.12987</td><td char="&#8211;" align="char">0.08595&#8211;0.17380</td><td char="." align="char">2.9280</td><td char="." align="char">0.0871</td><td char="." align="char">0.1600</td></tr><tr><td align="left">T&#8211;A</td><td char="." align="char">0.12661</td><td char="." align="char">0.24963</td><td char="." align="char">0.15200</td><td char="&#8211;" align="char">0.10509&#8211;0.19891</td><td char="." align="char">5.2672</td><td char="." align="char">0.0217</td><td char="." align="char">0.0500</td></tr><tr><td align="left">T&#8211;G</td><td char="." align="char">0.04809</td><td char="." align="char">0.11703</td><td char="." align="char">0.07367</td><td char="&#8211;" align="char">0.03953&#8211;0.10780</td><td char="." align="char">3.2455</td><td char="." align="char">0.0716</td><td char="." align="char">0.1400</td></tr></tbody></table><table-wrap-foot><p textid="47"><italic>Trait</italic> response to chemotherapy, <italic>Trait 1</italic> SD+PD <italic>n</italic>&#160;=&#160;83, <italic>Trait 2</italic> CR+PR <italic>n</italic>&#160;=&#160;30</p></table-wrap-foot></table-wrap>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 765 773 <span type="species:ncbi:9606">Patients</span>
###xml 962 969 <span type="species:ncbi:9606">patient</span>
###xml 1586 1594 <span type="species:ncbi:9606">patients</span>
###xml 1730 1738 <span type="species:ncbi:9606">patients</span>
###xml 2963 2970 <span type="species:ncbi:9606">patient</span>
Table 3 shows the frequencies of genotypes in different response patients, and the association of genotypes with the treatment response. (1) Genotype frequencies for both MRP2 and GSTP1 polymorphisms were found to be in Hardy-Weinberg equilibrium (HWE). Allele frequencies and HWE of each locus were shown in Tables 4 and 5. (2) The polymorphic genotypes of MRP2 (C-24T) and GSTP1 (Ile105Val) were significantly different between patients who responded and did not respond to the platinum-based treatment. After combining the heterozygous and homozygous variant genotypes, the difference remained statistically significant, suggesting that MRP2 (C-24T) and GSTP1 (Ile105Val) genotype differed between the two groups. (3) Genotype influences the treatment response. Patients carrying at least one variant allele (MRP2-C-24T C/T+T/T and GSTP1 A/G+G/G) were more likely to be responders compared with those who did not carry the variant allele; after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens, the OR for response were 4.493 and 2.881, and the 95% CI were between 1.728 and 11.682 (P = 0.002), and between 1.167 and 7.113 (P = 0.022), respectively. For other SNPs locus, however, the genotypes were not substantially different between the groups. (4) Table 6 displays statistics from case-control tests performed on each individual haplotype of MRP2 (C-24T) and GSTP1 (Ile105Val). A significant P value indicates that there is an association between the haplotype C-A (MRP2-24C and GSTP1105A) and the treatment response. The patients carrying MRP2-24C and GSTP1105A simultaneously were more to be non-responders.Table 3Genotype and response to chemotherapy among NSCLC patients (n = 113)GenotypeCasesResponse to chemotherapyOR (95% CI)P valueAdjusted OR (95% CI)Adjusted P valueCR + PR (%) n = 30SD + PD (%) n = 83MRP2 (C-24T) C/C6611 (36.7)55 (66.3)10.0154.069 (1.518-10.910)0.005 C/T4316 (53.3)27 (32.5)2.959 (1.211-7.246)0.02310.514 (0.842-131.319)0.068 T/T43 (10.0)1 (1.2)14.925 (1.425-166.667)0.0054.493 (1.728-11.682)0.002 C/T+T/T4719 (63.3)28 (33.7)3.390 (1.420-8.130)MRP2 (Val417Ile) G/G8420 (66.7)64 (77.1)1 G/A269 (30.0)17 (20.5)1.695 (0.654-4.386)0.2741.910 (0.697-5.229)0.208 A/A31 (3.3)2 (2.4)1.600 (0.138-18.519)0.5681.616 (0.115-22.779)0.722 G/A+A/A2910 (33.3)19 (22.9)1.684 (0.674-4.202)0.2621.879 (0.710-4.968)0.204MRP2 (Ile1324Ile) C/C7420 (66.7)54 (65.1)1 C/T338 (26.7)25 (30.1)0.864 (0.335-2.227)0.7621.066 (0.385-2.951)0.901 T/T62 (6.7)4 (4.8)1.350 (0.229-7.937)0.6651.508 (0.210-10.830)0.683 C/T+T/T3910 (33.3)29 (34.9)0.931 (0.385-2.252)0.8741.133 (0.441-2.911)0.796GSTP1 (Ile105Val) A/A7113 (43.3)58 (69.9)1 A/G3815 (50.0)23 (27.7)2.907 (1.200-7.042)0.0162.788 (1.106-7.029)0.030 G/G42 (6.7)2 (2.4)4.464 (0.574-34.483)0.1764.083 (0.457-36.463)0.208 A/G+G/G4217 (56.7)25 (30.1)3.030 (1.282-7.194)0.0102.881 (1.167-7.113)0.022Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimensTable 4Allele frequenciesLocusAlleleFrequencyStandard Error95% CIMRP2 (C-24T)C0.77430.02650.7168-0.8230T0.22570.02650.1770-0.2832MRP2 (Val417Ile)A0.14160.02380.0973-0.1903G0.85840.02380.8097-0.9027MRP2 (Ile1324Ile)C0.80090.02770.7434-0.8540T0.19910.02770.1460-0.2566GSTP1 (Ile105Val)A0.79650.02630.7434-0.8451G0.20350.02630.1549-0.2566Table 5Genotype frequenciesLocusGenotypeFrequencyHWD coeffStandard error95% CIMRP2 (C-24T)C/C0.5841-0.01550.0151-0.0459-0.0149C/T0.3805-0.01550.0151-0.0459-0.0149T/T0.0354-0.01550.0151-0.0459-0.0149MRP2 (Val417Ile)A/A0.02650.00650.0126-0.0165-0.0318A/G0.23010.00650.0126-0.0165-0.0318G/G0.74340.00650.0126-0.0165-0.0318MRP2 (Ile1324Ile)C/C0.65490.01350.0163-0.0185-0.0484C/T0.29200.01350.0163-0.0185-0.0484T/T0.05310.01350.0163-0.0185-0.0484GSTP1 (Ile105Val)A/A0.6283-0.00600.0146-0.0313-0.0218A/G0.3363-0.00600.0146-0.0313-0.0218G/G0.0354-0.00600.0146-0.0313-0.0218Table 6Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)HaplotypeFrequencies95% CIChi-squareP valueProb ExactTrait 1Trait 2CombinedC-A0.710740.433700.644460.58192-0.7070114.81400.0001<0.0001C-G0.114560.199630.129870.08595-0.173802.92800.08710.1600T-A0.126610.249630.152000.10509-0.198915.26720.02170.0500T-G0.048090.117030.073670.03953-0.107803.24550.07160.1400Trait response to chemotherapy, Trait 1 SD+PD n = 83, Trait 2 CR+PR n = 30
###end p 41
###begin p 42
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Genotype and response to chemotherapy among NSCLC patients (n = 113)
###end p 42
###begin p 43
###xml 54 61 <span type="species:ncbi:9606">patient</span>
Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens
###end p 43
###begin p 44
Allele frequencies
###end p 44
###begin p 45
Genotype frequencies
###end p 45
###begin p 46
Tests for haplotype-trait association between MRP2 (C-24T) and GSTP1 (Ile105Val)
###end p 46
###begin p 47
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait</italic>
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait 1</italic>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Trait 2</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Trait response to chemotherapy, Trait 1 SD+PD n = 83, Trait 2 CR+PR n = 30
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
One of the major obstacles of cancer chemotherapy is the development of drug resistance, which prevents the application of sufficient high doses to eradicate less-sensitive tumor cell populations. Interindividual differences in response to xenobiotics, which include many clinically used drugs, are extensive and represent a major problem in rational therapeutics. Such differences in many cases may be caused by inherited differences in enzymes and transporters, which function in drug elimination [24]. Owing to its possible effect on gene expression, we anticipated that polymorphisms of drug metabolizing enzymes genes and drug transporters genes may influence tumor response to platinum-based chemotherapy. The identification of molecular variables that predict either sensitivity or resistance to chemotherapy is of major interest in selecting the most likely effective first-line treatment.
###end p 49
###begin p 50
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
Some studies suggested that there is no difference whether cisplatin- or carboplatin-based chemotherapy regimens in the clinical efficacy [25, 26]. Moreover, the results tend to be similar whether the partner drug is paclitaxel, docetaxel, or gemcitabine. Similar results are generally obtained with carboplatin [25-27]. Hence, the data of these 113 patients were analyzed as a combination group.
###end p 50
###begin p 51
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
Glutathione S-transferases are crucial for the cell defence system. These phase II detoxification enzymes are involved in the detoxification of a variety of chemotherapeutics including platinum. In vitro analyses revealed a significant association between high GSTP1 expression of tumor cells and decreased sensitivity to platinum agents [28]. Cisplatin is detoxified by glutathione through adduct formation [29]. GSTP1 interacts with platinum-based compounds [30], and glutathione-conjugated platinum can be quickly effluxed from cells [31]. Thus, it is plausible that high GST activity may result in more rapid drug metabolism that diminishes the cytotoxic effects of chemotherapy on tumor cells [32].
###end p 51
###begin p 52
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
Multidrug resistance-associated protein 2 is responsible for the intracellularly formed glucuronide and GSH conjugates of clinically important drugs. MRP2 is expressed in many tumor tissues, and the tumor cells overexpressing MRP2 might acquire the multidrug resistance [18]. A significant correlation has been observed between MRP2 mRNA levels and cisplatin resistance in colorectal carcinoma [33] suggesting that MRP2 contributes to resistance against treatment with the chemotherapeutic drugs.
###end p 52
###begin p 53
Because the important factors influencing interindividual differences in the drug disposition, many analyses of SNPs of drug metabolizing enzymes and drug transporters have been performed.
###end p 53
###begin p 54
###xml 14 16 14 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1154 1156 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 1087 1093 <span type="species:ncbi:9606">people</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
Board et al. [34] first identified the GSTP1 polymorphisms. Alterations in the structure, function, or expression levels of GSTP1 due to genetic polymorphisms could alter the ability to detoxify chemotherapeutic agents and modulate drug response. The Ile105Val GSTP1 polymorphism, an A/G SNP located within the substrate binding domain of GSTP1 at position +313 within exon 5 results in an amino acid substitution of isoleucine by valine at codon 105 of the enzyme. This substitution has been shown to significantly influence the catalytic activity and thermal stability of the enzyme and to affect the conjugation capacity of GSTP1 for certain substrates, including platinum agents [35, 36]. Rather than being present or absent, the GSTP1 gene has alleles that encode enzymes with different activities. The highest level of GSTP1 activity is seen in individuals with homozygous wild genotype (Ile/Ile). The activity is somewhat reduced in heterozygotes (Ile/Val) and further diminished for those with homozygous mutant genotype (Val/Val) [35]. It is estimated that approximately 50% of people have either one or two valine alleles (Ile/Val or Val/Val) [37]. Thus, this polymorphism is linked to clinical outcome of patients who received platinum-based chemotherapy [38, 39]. Individuals with these variant GSTP1 genotypes that result in reduced GST enzymatic activity may be good responders due to decreased detoxification of chemotherapeutic agents.
###end p 54
###begin p 55
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 421 428 <span type="species:ncbi:9606">patient</span>
Based on this, we hypothesize that lung cancer patients with GSTP1 Ile105Val polymorphisms conferring low activity may have a more favorable prognosis. Our result confirmed this hypothesis. We suggest that this might occur due to the reduced metabolism and slower removal of chemotherapeutic agents, which would yield a prolonged cytotoxic effect; this could lead to a better treatment response and subsequently improved patient survival. Homozygous mutants of GSTP1 (Ile105Val) showed no effect on treatment response, probably the numbers were too small to identify such an effect. Therefore, we are enlarging the samples to confirm the results.
###end p 55
###begin p 56
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1367 1369 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 1526 1528 1524 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 1530 1532 1528 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 1767 1769 1765 1767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 1922 1924 1920 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
The MRP2 gene is located on chromosomal locus 10q24 and consists of 32 exons (31 coding exons) and spans 69 kb. SNP analysis of MRP2 has been performed, and numerous SNPs have been identified [40, 41]. A recent study provided detailed information on ABCC2 variations and haplotype structures in Japanese [42]. Because of its importance in determining the disposition of anionic drugs, and as a consequence, in determining the pharmacological and/or adverse effects of substrate drugs, correlations between genotype and phenotype need to be established [40]. However, although several studies have suggested the association of SNPs with altered MRP2 expression or function, knowledge about biochemical consequences is still very poor and their association with clinical phenotype remains to be clarified. The functional analysis of these SNPs mutants of MRP2 still remains to be performed. Among several kinds of MRP2 SNPs, C-24T (promoter), G1249A (exon 10) and C3972T (exon 28) are frequently observed [41, 43]. Their allele frequency is 18.8, 12.5, and 21.9%, respectively. In this paper, the allele frequency found in this population is 22.6, 14.2, and 19.9%, respectively, which is similar to the literature. G1249A polymorphism is a G-->A base change that results in amino acid alterations from Val to Ile at 417, and 1,249 AA is associated with decreased mRNA [44]; whereas C3972T is the 'silent' mutation at 1,324 (Ile1324Ile). several studies have suggested their association with altered MRP2 expression or function [45, 46]. Besides being able to quickly export glutathione-conjugated platinum, upregulated expression of MRP2 is also associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in the cisplatin-resistant cell lines [47]. Amino acid substitution due to SNPs might weaken this effectiveness, and therefore, might enhance the sensitivity to platinating agents. Yang et al. [48] reported that variant in exon 10 (G1249A) was significantly correlated with response to chemotherapy. We also have analyzed these three frequent SNPs in MRP2 gene to investigate their significance in chemosensitivity to platinum-based chemotherapy. Different from Yang's result, however, our results indicate that the mutant alleles in promoter (C-24T) was significantly related to sensitiveness of NSCLC to therapeutic agents, while the SNPs in exon 10 (G1249A) and exon 28 (C3972T) were not associated with response to chemotherapy. In this study, the presence of the A allele in exon 10 showed a similar trend of better response. However, it is statistically impossible to find the differences of the chemotherapeutic efficacy among variant genotype. We think that there should exist other mechanisms that contribute to the complicacy of the result. For example, most MRP2 substrates are also transported by OATP2 (organic anion transporting polypeptide), so the SNPs and/or inter-individual differences in the expression level of OATP2 maybe also need to be analyzed simultaneously.
###end p 56
###begin p 57
###xml 144 152 <span type="species:ncbi:9606">patients</span>
Our observation suggests that the polymorphic status of GSTP1 Ile105Val and MRP2 C-24T might predict treatment response of advanced stage NSCLC patients. Moreover, there is an association between the haplotype C-A (MRP2 -24C and GSTP1 105A) and the response to chemotherapy. However, the limitation of our study must be acknowledged. Usually, in the retrospective study, it may be more precise and objective to evaluate the overall survival and progression-free survival as prognostic factors. Considering the difficulty in clinical practice, we chose chemotherapy response as end point of prediction, which was also critical to illuminate the mechanism affected outcome. Ideally, validation studies should be carried out to measure such parameters as predictive and prognostic factors which is also the expected aim of our next research. Therefore, larger sample size and prospective studies, the independent collection of clinical outcomes data and genotyping, and in vivo functional studies are needed to confirm the results and identify the clear biological basis of these findings.
###end p 57
###begin p 58
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1678 1680 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1682 1684 1682 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 1686 1688 1686 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
Here, we used a new gel-based DNA microarray genotyping method, reported by Xiao et al. [23], for gene mutation analysis and functional SNP screening. This method based on Rehman's idea [49]was improved and gave a uniform sample concentration and viscosity for all of the spots on microarrays during spotting, and had a much lower fluorescent background as well as higher S/N (signal/noise). According to the report, by modifying the process for immobilization of nucleic acids, a high quantity microarray with a uniform sample concentration of spots is fabricated. The gel immobilization of nucleic acids has a high immobilization yield and good hybridization efficiency. PCR products modified with acrylamide groups can be used in parallel for gel immobilization to prepare the microarray, in which PCR products are purified only by ethanol precipitation or even untreated. As an alterative to conventional washing, electrophoresis effectively removed the non-specifically bound targets in hybridization and therefore reduce the high background after hybridization, so that the power for discriminating single-nucleotide mismatch is significantly enhanced. Different genotypes of an SNP have successfully been determined by the ratio of signal intensities from two allele-specific oligonucleotides labeled with different dyes. When compared with the common used genotyping methods, such as TagMan assay, PCR-RFLP (restriction fragment length polymorphism), this method is simple, rapid, robust, efficient, and cost-effective for the detection of single-nucleotide mismatch, extremely powerful in genotyping of large-scale samples, and could be used with high reproducibility [23, 50, 51].
###end p 58
###begin p 59
This work was financially assisted by the Prophase Force-Study program of Jiangsu Province Nature Fund (grant BK2005203), by the Medicine Science Technology Research "Eleventh Five-Year" Program of PLA (No. 06MA111) and by the Focal Project of Nanjing Medicine Technology Development (grant ZKX05030)
###end p 59
###begin p 60
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conflict of interest statement</bold>
Conflict of interest statement The authors indicated no potential conflicts of interest.
###end p 60
###begin p 61
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 61
###begin title 62
References
###end title 62
###begin article-title 63
The world health report 2002: reducing risks, promoting healthy life
###end article-title 63
###begin article-title 64
The treatment of advanced non-small cell lung cancer
###end article-title 64
###begin article-title 65
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results
###end article-title 65
###begin article-title 66
Molecular mechanisms of resistance and toxicity associated with platinating agents
###end article-title 66
###begin article-title 67
The role of p53 in treatment responses of lung cancer
###end article-title 67
###begin article-title 68
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Glutathione-S transferase family of enzymes
###end article-title 68
###begin article-title 69
Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways
###end article-title 69
###begin article-title 70
Nomenclature for mammalian soluble glutathione transferases
###end article-title 70
###begin article-title 71
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue
###end article-title 71
###begin article-title 72
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Immunohistochemical localization of glutathione S-transferases in human lung cancer
###end article-title 72
###begin article-title 73
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia
###end article-title 73
###begin article-title 74
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Molecular epidemiology of the human glutathione S transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
###end article-title 74
###begin article-title 75
The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation
###end article-title 75
###begin article-title 76
###xml 99 102 <span type="species:ncbi:10116">rat</span>
Inhibition of Mrp2- and Ycf1p-mediated transport by reducing agents: evidence for GSH transport on rat MRP2
###end article-title 76
###begin article-title 77
###xml 25 30 <span type="species:ncbi:9606">human</span>
Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1): evidence that a tri-glutathione conjugate is required
###end article-title 77
###begin article-title 78
Expression and function of efflux drug transporters in the intestine
###end article-title 78
###begin article-title 79
A family of drug transporters: the multidrug resistance-associated proteins
###end article-title 79
###begin article-title 80
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin resistant human cancer cell lines with decreased drug accumulation
###end article-title 80
###begin article-title 81
###xml 20 25 <span type="species:ncbi:9606">human</span>
Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions
###end article-title 81
###begin article-title 82
Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer
###end article-title 82
###begin article-title 83
Reporting results of cancer treatment
###end article-title 83
###begin article-title 84
An improved gel-based DNA microarray method for detecting single nucleotide mismatch
###end article-title 84
###begin article-title 85
Pharmacogenomics: translating functional genomics into rational therapeutics
###end article-title 85
###begin article-title 86
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
###end article-title 86
###begin article-title 87
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial
###end article-title 87
###begin article-title 88
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
###end article-title 88
###begin article-title 89
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Glutathione S transferase-pi gene expression and platinum drug exposure in human lung cancer
###end article-title 89
###begin article-title 90
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance
###end article-title 90
###begin article-title 91
###xml 30 31 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 110 115 <span type="species:ncbi:9606">human</span>
Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells
###end article-title 91
###begin article-title 92
###xml 53 61 <span type="species:ncbi:9606">patients</span>
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer
###end article-title 92
###begin article-title 93
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
###end article-title 93
###begin article-title 94
###xml 108 113 <span type="species:ncbi:9606">human</span>
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas
###end article-title 94
###begin article-title 95
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14
###end article-title 95
###begin article-title 96
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution
###end article-title 96
###begin article-title 97
###xml 28 29 28 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukaemia
###end article-title 97
###begin article-title 98
Metabolic gene polymorphism frequencies in control populations
###end article-title 98
###begin article-title 99
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer
###end article-title 99
###begin article-title 100
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
###end article-title 100
###begin article-title 101
Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition
###end article-title 101
###begin article-title 102
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
###end article-title 102
###begin article-title 103
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population
###end article-title 103
###begin article-title 104
Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 59-untranslated region and exon 28
###end article-title 104
###begin article-title 105
###xml 39 44 <span type="species:ncbi:9606">human</span>
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation
###end article-title 105
###begin article-title 106
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex
###end article-title 106
###begin article-title 107
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
###end article-title 107
###begin article-title 108
Overexpression of cMOAT(MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin
###end article-title 108
###begin article-title 109
Single nucleotide polymorphisms in MRP2 gene and their significance on chemosensitivity of advanced ovarian cancer
###end article-title 109
###begin article-title 110
Immobilization of acrylamide-modified oligonucleotides by co-polymerization
###end article-title 110
###begin article-title 111
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray
###end article-title 111
###begin article-title 112
Bisulfite modification of immobilized DNAs for methylation detection
###end article-title 112

